Page 1

Fifteen and Forward* 2011 Annual Report

*Celebrating 15 years, 1996–2011


“When I came on board in 1997, it was just the executive director, Anne Alexander, and me. In the beginning, we were known as the National Foundation for Biomedical Research. We had nine donors and started with $200,000. The NIH gave us office space on its campus in Building 60—the Cloister—and we had our first board meeting in the chapel. Some of the early programs included the Clinical Research Training Program (CRTP), made possible by funding from Pfizer Inc; The Biomedical Engineering Summer Internship Program, made possible by a grant from the Whitaker Foundation and the Neuroimmunology Fellowship supported by the Penates Foundation. Mrs. Lenore Salzman set up a memorial fund very early on as a tribute to her late husband, Dr. Norman P. Salzman, to support an award and symposium in Virology. I’ve met so many wonderful people—originally I got to see every one of the CRTP Fellows once a month when they picked their checks up from me. I was chatting once with one of the CRTP Fellows, Dr. Eric Eskiolgu, and I told him that one of my heroes was pediatric neurosurgeon Dr. Benjamin Carson and that I had read some of his books and gone to one of his lectures. He said, ‘Oh, I’m meeting with him today.’ He came back with a business card signed by him, which I treasure to this day. Where we started and what we’ve become is just amazing. We helped build the Edmond J. Safra Family Lodge with funding from Mrs. Lily Safra and the Edmond J. Safra Philanthropic Foundation. To see the lodge go from what was just a parking lot to this incredible building was mind-boggling. We’ve had so many, many, many accomplishments—the mHealth Summit, the Bill & Melinda Gates Foundation grants—really it’s just the tip of the iceberg. To say the least, we have come a long way from our humble beginning, and I have such appreciation and pride for the Foundation. I know we are making a difference in this world.” PEGGY J. GERLACHER Operations Associate and longest-serving FNIH staff member


Fifteen and Forward: Progress Through Partnerships Established by Congress to assist the National Institutes of Health (NIH) in its mission of improving human health, the Foundation for the NIH (FNIH) has steadily built upon its modest fundraising beginnings in 1996 to become a diverse and dynamic organization, both highly efficient and effective

“By facilitating world class collaborations

in its work. We have evolved into a unique and

between the public and private sectors,

innovative designer and manager of the

the FNIH is able to bring together the

creative and complex partnerships that today’s health challenges demand. Guided by the priorities and goals of the NIH, our job is to identify and tackle urgent biomedical problems whose solutions are

most innovative minds in science. Through these diverse partnerships, the FNIH is able to address some of the most critical health issues facing patients and their families.”

beyond the reach of any single entity or organization.

ELLEN SIGAL, Ph.D.

Operating outside the confines of a federal agency,

Board Member, Foundation for the National Institutes of Health; Chair, Friends of Cancer Research

we can surmount the barriers between the public and private sectors to bring together the best ideas, resources and funds.

As a neutral convener among partners, we serve an important function in preventing conflicts of interest on the one hand, and preserving proprietary integrity on the other. This allows us to combine the talents and efforts of nontraditional collaborators—and even competitors—around a common goal. In addition to the NIH, our partners include other federal agencies, universities, institutes, corporations, foundations, associations and individuals. The role of the FNIH varies according to the nature and needs of the particular partnership from discrete tasks such as raising funds and organizing meetings, to grant making, scientific oversight and overall program leadership. We work with nearly all 27 institutes and centers of the NIH, on programs large and small, from projects focused on training and education, to clinical trials seeking discoveries in mental health, cancer and many other diseases, to multi-site global initiatives affecting millions of people and embracing scores of partners. While each is unique, our partnerships all are built around impact, feasibility and inclusiveness. All stakeholders are integral partners in our programs, from beginning to end. Our Board of Directors is populated with eminent scientists, scholars, business people and philanthropists who ensure that each project meets stringent standards and benchmarks for success. By bringing world-class resources to bear, the Foundation for the NIH and its partners are accelerating the pace of biomedical research and advancing human health around the globe.

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 1


and Forward

Letter From the Chairman

2 | 2011 ANNUAL REPORT


As the boundaries between traditional

recognize undocumented drug reactions

disciplines of science continue to fall away—

(Observational Medical Outcomes Partnership,

and indeed, new disciplines

OMOP). At the same time, we support basic

emerge—the biomedical

science, making available important tools,

discovery horizon stretches in

such as expansive tissue and data libraries, to

seemingly limitless directions.

investigators around the world (ADNI, CTC-

Computational biology,

VIMC, OMOP).

bioengineering, nanoscience, proteogenomics and a host of other convergent fields present immediate, promising and unprecedented avenues toward understanding and advancing human health. The Foundation for the NIH—specifically created to foster broad research collaboration through public-private partnerships—is at the nexus of this revolution. In our 15-year lifetime, we have supported and enabled some of the most important recent initiatives of the National Institutes of Health—including the Human Genome Project, the Genetic Association Information Network (GAIN), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Scientists we support collaborate on six continents—in state-of-the-art laboratories, in poverty-wracked communities and in dense tropical rainforests to address health challenges both localized and global. Since our founding in 1996, we have raised more than $600 million in support of over 400 projects. Through the years, we have evolved to not only raise money for ongoing NIH activities such as research, training, lectures and patient support, but to develop programs that leverage NIH expertise in innovative ways, partnering with insurers and health plan providers, for

We engage some of the most prominent entities in their fields—not only our stalwart partners in the pharmaceutical industry and nonprofit organizations such as the Bill & Melinda Gates Foundation, but corporate leaders such as Intel, Verizon and Coca-Cola, which bring novel resources such as wireless technology and public awareness components to public health initiatives. In an era of tight federal funding, we continue to find new, creative ways to deliver critical support to NIH institutes and programs—from in-kind drug donations to the NIH Clinical Center and room–naming opportunities at the Edmond J. Safra Family Lodge to video-link training classes and online tutorials. Even as we strive to respond to the needs of the NIH, we maintain a detailed and rigorous protocol for evaluating the suitability, feasibility and progress of all potential programs. In this way, we ensure that our efforts and resources—and, most importantly, those of our partners—are employed to do the greatest good. As we mark our 15-year milestone and move forward, we are well positioned to support the NIH and biomedicine across the full spectrum of existing and yet-to-be-identified challenges, and thereby contribute to the betterment of human health.

example, to examine medical records to

Charles A. Sanders, M.D. Chairman

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 3


Research From fundamental science that peers deep into the recesses of cells to clinical trials that confirm the safety and efficacy of new patient therapies, the FNIH creates partnerships that address the world’s most pressing biomedical challenges. Forming collaborations uniquely suited to the task at hand, the Foundation can find ways to support research into basic biochemical processes as well as diseases of global epidemic proportion. Embracing an ever wider universe of partners, the FNIH is helping the NIH to inform not only medical science, but regulatory and policy-making agencies that directly impact health care delivery.

4 | 2011 ANNUAL REPORT


The Biomarkers Consortium Five years since its formation, the Biomarkers Consortium has had a major impact on advancing biomarkers as tools for improving medicine, having launched 14 projects worth over $45 million. Consortium projects focus on clinical application and regulatory qualification of biomarkers, which allows their practical application in streamlining the development of new treatments and providing more effective patient care.

Biomarkers are physiologic traits that enable

infection, community-acquired bacterial

researchers to identify and track both normal

pneumonia (CABP) and acute bacterial skin

and abnormal processes within the body.

and skin structure infections (ABSSSI). It also

Developing these markers is critical to advancing

approved the launch of the second phase

our understanding of practically all major illnesses

of this project, which will seek to develop

and diseases—from bacterial infections to

new tools to measure these outcomes for

Alzheimer’s disease to cancer. Biomarkers

use in clinical trials;

also can play a significant role in determining the effectiveness and safety of new drugs, thereby hastening the development of new— and better targeted—treatments.

• initiated qualification with the FDA of FDGPET and Volumetric CT imaging as markers for disease progression and response to therapy in non-Hodgkin’s lymphoma and non-small cell

Collaborative science is essential to the

lung cancer. This effort is making use of data

development and qualification of biomarkers.

from two, five-year clinical studies managed

The FNIH-managed Biomarkers Consortium

by the National Cancer Institute and funded

brings together the resources and expertise

through the Consortium;

of the NIH, the U.S. Food and Drug Administration (FDA), and Pharmaceutical Research and Manufacturers of America (PhRMA) as founding partners, as well as many other participants from industry, academia, nonprofit organizations and other government institutions. In 2011, the Biomarkers Consortium: • completed its Alzheimer’s Disease Plasma Proteomics Project. This project utilized blood samples from the groundbreaking Alzheimer’s Disease Neuroimaging Initiative to qualify biomarkers useful in diagnosing and monitoring patients; • submitted interim recommendations to

• launched the Beta Cell Mass and Function Project, which is an effort to standardize methods that measure pancreatic beta cell function and open the door to the development of new treatments for diabetes. The ability to track the performance of these insulin-producing cells should allow for better detection and monitoring of the progression of diabetes; and • launched the Kidney Safety Biomarkers Project, a major collaboration with the Critical Path Institute to qualify new urinary biomarkers of acute drug-induced kidney injury, enabling more efficient development of safer drugs for a

the FDA for measuring clinical outcomes

broad range of diseases.

of treatments for two common types of

(continued on page 6)

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 5


and Forward

The Biomarkers Consortium (continued from page 5)

“The FNIH Biomarkers Consortium has

In addition to the CABP and ABSSSI project,

set the stage for real progress in the biomarker ‘pipeline’ by bringing together

the Consortium approved two other initiatives for launch in 2012. The Osteoarthritis

teams of highly qualified people to both

Biomarkers Project will utilize the extensive

identify critical barriers stopping or

resources of another public-private partnership, the Osteoarthritis Initiative, to

slowing development and creating

find better ways to predict, measure and

the necessary projects to address

treat this leading cause of disability in older

them. The Biomarkers Consortium

adults. The Atherosclerosis In Silico Modeling

has led a new generation of

Project will evaluate the significance of

pre-competitive partnerships that

many different biomarkers involved in the

leverage the FNIH’s position as a trusted third party, and is producing important

progression and treatment of atherosclerosis using advanced computer modeling techniques. Cardiovascular disease, including

processes, tools and databases that

atherosclerosis, is the leading cause of

are available to all of the relevant

death in the United States. This work should

communities. Altogether a great story!”

support the design of better treatments.

ANNA D. BARKER, Ph.D. Former Deputy Director of the National Cancer Institute, Current Professor and Director of Arizona State University’s Transformative Healthcare Networks; and Co-Director, Complex Adaptive Systems Initiative

The Biomarkers Consortium Members Abbott Laboratories

AstraZeneca

Academy of Molecular Imaging

Autism Speaks

Advanced Medical Technology Association Alzheimer’s Association American Association for Cancer Research

Avon Foundation Banyan Biomarkers Battelle Memorial Institute BG Medicine Biotechnology Industry Organization

Federation of Clinical Immunology Societies GlaxoSmithKline Hoffman-LaRoche/The Roche Group International Society of Biological Therapy of Cancer Johnson & Johnson

Orasi Medical, Inc. Osteoarthritis Research Society International Pfizer Inc Pharmaceutical Research and Manufacturers of America PROOF Centre of Excellence Radiological Society of North America

Boehringer-Ingelheim

Juvenile Diabetes Research Foundation

American Orthopaedic Society for Sports Medicine

Bristol-Myers Squibb

Kidney Cancer Association

Celgene Corporation

American Society of Clinical Oncology

CHDI Foundation

The Leukemia and Lymphoma Society

Daiichi-Sankyo, Inc.

Merck and Co., Inc.

Dairy Research Institute

Metanomics Health GmbH

United States Pharmacopeial Convention

Eisai, Inc.

Michael J. Fox Foundation for Parkinson’s Research

University of Illinois

American Diabetes Association

Amgen Amylin Pharmaceuticals Arthritis Foundation Association of Clinical Research Organizations

6 | 2011 ANNUAL REPORT

Eli Lilly and Company

Ontario Cancer Biomarker Network

RareCyte, Inc. Rules-Based Medicine Sunovion Pharmaceuticals Takeda Pharmaceuticals

XOMA, Ltd.


Comprehensive T Cell Vaccine Immune Monitoring Consortium As the research community has come to

support the broad collaborative activities of NIH

recognize that the most efficient way to

intramural laboratories.

overcome the difficult problem of creating an AIDS vaccine is through collaboration and the sharing of information, tools and materials, the FNIH has played a key role in facilitating partnerships among leading HIV/AIDS researchers through several collaborative projects. The FNIH was first approached in 2005 by Dr. Richard Koup, Chief of the Immunology Lab at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, for assistance in managing a proposal to the Bill & Melinda Gates Foundation’s newly established Collaboration for AIDS Vaccine Discovery (CAVD). The CAVD was founded to bring the “big science” approach used to

Completing its first five years in June 2011, the CTC-VIMC has achieved its objectives as a central service facility supporting the entire CAVD. The consortium: • harmonized and standardized key assays for evaluating T cell responses across four clinical core laboratories and the three non-human primate core laboratories and published these landmark achievements; • developed new molecular technologies to evaluate immune responses, and applied these methods to the RV144 “Thai” trial, which provided the first indication that a vaccine for AIDS could be effective;

sequence the human genome to bear on

• established a new blood cell repository,

the scourge of HIV/AIDS. Koup’s proposal

a non-human primate cell and tissue

was to establish the Comprehensive T Cell

repository, and a reagent core, all of which

Vaccine Immune Monitoring Consortium (CTC-

support research and assay standardization

VIMC), a collaboration among leading HIV

efforts across the entire CAVD network; and

T cell immunologists who would work to standardize cellular immunological methods for monitoring HIV vaccine trials in humans and non-human primates.

• is providing an array of immunological assays to CAVD-supported Phase 1 clinical trials and non-human primate vaccine development initiatives.

Awarded in the spring of 2006, this was the

Earlier in 2011, the FNIH was invited to submit

largest of the 26 CAVD awards: $33 million to

a proposal to continue the work of CTC-VIMC.

support the work of 19 international investigators

This was favorably reviewed, and a new award

in 14 institutions. The FNIH assumed

of $16.8 million has been granted to maintain

responsibility for the Administrative Core:

this key component of the CAVD infrastructure

• developing sub-award agreements with

through 2016.

consortium collaborators; • participating in the development of CAVD guidelines to protect intellectual property while promoting the availability of health innovations to those most in need; and • monitoring fiscal expenditures across the consortium. A dedicated project manager was added to the FNIH team, to play a vital role in advancing the project’s research agenda, working closely with Dr. Koup to facilitate communication among investigators, evaluate progress toward preestablished project milestones and document

“Partnering with the FNIH has enabled the VRC to lead the CTC-VIMC—a major international consortium where shared ideas are aligned with clinical development priorities and rigorous standards are established for AIDS vaccine testing.” RICHARD KOUP, M.D. CTC-VIMC Principal Investigator; Chief of the Immunology Laboratory at the Vaccine Research Center at the National Institutes of Health

the consortium’s scientific achievements. This relationship exemplifies the FNIH’s ability to Foundation for the National Institutes of Health

W W W . F NIH . OR G | 7


and Forward

Centralized Envelope Comparative Immunogenicity Phase 1 Trial The Centralized Envelope Comparative

Vaccine Research Center, EuroVacc and

Immunogenicity Phase 1 Trial (CECI) is another

Sanofi-Pasteur.

Collaboration for AIDS Vaccine Discovery (CAVD) program administered by the FNIH. The project focuses on clinical testing of a novel vaccine

This proof-of-concept clinical trial will determine the relative efficacy of the innovative, computergenerated “mosaic” vaccine insert against the

developed through the use of computational biology to overcome the vaccine-development challenges arising from the genetic diversity of the HIV virus.

naturally occurring wild type virus and a third “consensus” HIV vaccine insert that represents the most frequently circulating HIV strains. The study could pave the way for faster regulatory clearance of future trials designed using

Approved in November 2009, this

computational biology and substantially reduce

$6 million project brings together

the timeline for testing new HIV vaccines.

a new mix of investigators and

CECI demonstrates how the FNIH can facilitate

institutions, including many major

external collaboration with an extramural branch

stakeholders of the Global HIV/

of the NIH, in this case NIAID’s Division of

AIDS Vaccine Initiative: the CAVD,

Acquired Immunodeficiency Syndrome.

the National Institute of Allergy and Infectious Diseases (NIAID), the NIAID-supported Center for HIV/AIDS Vaccine Immunology (CHAVI), the HIV

Manufacture of the test HIV vaccines is well underway, with plans to begin the

Vaccine Testing Network (HVTN), as well as the

clinical trial in 2013.

Development of a Second Generation Broadly Neutralizing Antibody Product to Prevent HIV-1 Infection Study by leading researchers, including several

The Development of a Second Generation

at the Vaccine Research Center (VRC) of “non-

Broadly Neutralizing Antibody Product to

progressors”—those rare individuals infected

Prevent HIV-1 Infection is a five-year, $1.8 million

with HIV who do not become sick—has pointed

effort to harness one such antibody to better

to the role of broadly neutralizing antibodies in

understand this phenomenon and produce

halting disease progression to full-blown AIDS.

new tools for the fight against AIDS. Its aim is

8 | 2011 ANNUAL REPORT

The Norman P. Salzman Memorial Award and Lecture in Virology are established; the events are supported by the newly established Norman P. Salzman Memorial Fund.

Congress approves name change from the National Foundation For Biomedical Research to the Foundation for the National Institutes of Health.

The FNIH broadens its portfolio to include biomedical research programs, launching fundraising and partnership development for the Osteoarthritis Initiative, a $60 million public-private partnership involving the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA) and other agencies together with four industry partners. The FNIH raises $20.8 million from the private sector for this project.

The FNIH begins fundraising for construction of what will become the Edmond J. Safra Family Lodge.

2000

The National Foundation For Biomedical Research (NFBR) is formed. Established by the United States Congress to support the mission of the National Institutes of Health—improving health through scientific discovery—the Foundation identifies and develops opportunities to leverage NIH resources.

1999

A Timeline of Highlights

The NFBR launches its first major program— the Clinical Research Training Program (CRTP). To date, the CRTP has enabled 340 of the country’s most promising medical and dental students to experience clinical research firsthand in an intensive, year-long residential training program at the NIH.

1998

1996

1997

Fifteen and Forward |

The FNIH supports the Mouse Sequencing Genome Project.


to enhance the potency, efficacy and eventual

partnership with the Bill & Melinda Gates

clinical utility of the VRC01 monoclonal antibody

Foundation and the NIH. With scientific

through genetic modification.

leadership at the National Institute of Allergy

Launched in November 2011 under the Collaboration for AIDS Vaccine Discovery program, this new project is an FNIH

and Infectious Diseases’ VRC, collaborators include Brigham and Women’s Hospital and the University of Minnesota.

Observational Medical Outcomes Partnership The Observational Medical Outcomes Partnership

and network of data partners with access to de-

(OMOP) was conceived in 2007 and established in

identified observational data representing nearly

late 2008 as a public-private research partnership

200 million patients.

between the FDA, PhRMA and the FNIH. Entering its fourth year of operations, the effort continues to build upon its existing research base by advancing methodological research, sustaining and improving the accessibility and framework of the OMOP Research Lab, and enhancing and expanding OMOP’s tools and capabilities. OMOP’s mission is to inform the implementation of a systematic medical product surveillance system with empirical evidence of the appropriate methods, data and infrastructure necessary to identify and track potential relevant safety issues. OMOP is one of the most ambitious initiatives in the field, whose research agenda is addressing data, methods, infrastructure and governance questions in an open, scientific collaboration.

The impact of OMOP goes beyond specific study findings, however. “We’ve created a very unique resource, an open-source research environment,” says OMOP Executive Director Thomas Scarnecchia. “We’ve built a dynamic community of methodologists, forged new partnerships with others that go beyond drug safety-related research.” OMOP’s framework for organizing, characterizing and analyzing disparate data sources across a network of health care and insurance providers is now being extended and adopted by four academic and nonprofit health care research networks within the U.S. and Europe. This growing adoption of OMOP’s framework, coupled with the partnership’s open and transparent research

For the past three years, OMOP has established

culture, enables OMOP to foster a diverse

and engaged a diverse research community,

community of researchers working together to

guided by a robust governance model with

advance the science of observational studies

broad stakeholder representation across two

and integrate the new knowledge into improved

advisory boards and an executive board. OMOP

standards and practices.

now serves as a unique resource to foster methodological research that includes a secure

The Helix and the Genome: 50 Years from Model to Medicine celebration includes gala dinner, symposia, exhibits, outreach activities and more.

The FNIH begins fundraising for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), ultimately raising $27 million for this program. See page 16.

Foundation for the National Institutes of Health

2005

The Grand Challenges in Global Health (GCGH) initiative is established with a $200 million grant from the Bill & Melinda Gates Foundation. The GCGH encourages innovation to solve persistent health problems in the developing world. See page 10.

2004

“Celebrating 50 Years of Neuroscience Research” event commemorating the 50th anniversaries of NINDS and NIMH.

2003

2001

high-performance research computing laboratory

Edmond J. Safra Family Lodge welcomes its first guest.

The FNIH announces the GCGH grantees.

The Imaging Database Resources Initiative (IDRI) launches to improve lung cancer diagnosis and treatment by encouraging development of advanced medical imaging software tools.

Dean R. O’Neill Renal Cell Cancer Research Fund and Dr. Edward T. Rancic Memorial Fund are established to raise funds for kidney cancer research. See page 34.

W W W . F NIH . OR G | 9


and Forward

Grand Challenges in Global Health The Grand Challenges in Global Health (GCGH)

At the organizational stage, for example,

initiative encourages scientists from around the

the FNIH:

world to address and overcome some of the obstacles that block progress against diseases that affect populations in the developing world. GCGH represents a major milestone in the development of the FNIH. Established with the

• managed the “call for ideas,” and processed more than 1,000 Grand Challenge suggestions from 75 countries; • organized and staffed the GCGH Scientific

Bill & Melinda Gates Foundation in 2003, the

Board, comprising global health experts

partnership not only introduced the largest grant

from around the world;

made to date to the FNIH, but it challenged the FNIH to broaden its support of partnerships through functions well beyond fundraising.

• solicited and reviewed 1,500 letters of intent containing proposed solutions to the Grand Challenges; and • invited and organized peer review for 405 grant proposals. By 2005, additional partners included the Wellcome Trust and the Canadian Institutes of Health Research. The FNIH assumed ongoing responsibility for both the scientific and financial oversight of 20 of the original 43 GCGH projects, operating in 25 countries. FNIH-supported investigators worked to: • improve upon existing vaccines so as not to require refrigeration or administration by needle; • advance vaccine development through design of more protective antigens;

Sharing with the Bill & Melinda Gates Foundation a focus on innovation, feasibility and impact, the FNIH built new institutional capacity for: • scientific project and program management; • grant making and administration; and • global health initiatives.

• develop biologic, genetic and chemical strategies to control disease transmission by insect vectors; • develop drugs and delivery systems that minimize the likelihood of resistance; and • create immunological methods to cure chronic infections. Today, six years after their launch, many of these projects have met their scientific goals and are delivering promising results in the global

10 | 2 0 1 1 A N N U A L R E P O R T


fight against infectious disease. Researchers at the Rockefeller University, N.Y., for example,

“Under the GCGH initiative we’ve taken a completely new concept, in directly

have advanced a new HIV/AIDS prototype

targeting dendritic cells—those

vaccine to clinical trial. Phase 1 clinical trials have also been approved in India for

cells that stimulate the immune

a temperature-stable measles vaccine that

system—to work on developing a

can be delivered by the respiratory route. Even as the initial projects draw to a close, the FNIH’s role in GCGH continues to evolve. In 2009, the Bill & Melinda Gates Foundation provided supplemental funding to extend the

vaccine for HIV. Unlike smallpox— for example—with HIV, natural infection does not confer durable immunity. If you are exposed, you could get it again and

partnership component working to develop

again. Our attempt is to achieve

novel control methods against mosquito

immunity that is better than that

vectors of disease. That partnership is known as Vector-based Control of Transmission: Discovery Research, or VCTR. In addition, the FNIH expertise honed through GCGH has led to several other global health research partnerships in collaboration with the NIH, the Gates Foundation, universities, research institutes and biotechnology companies around the world.

conferred by natural infection with this novel approach. Our first clinical trial is virtually finished, with 45 people receiving the vaccine.” SARAH SCHLESINGER, M.D. Clinical Study Director, Improved Vaccine Efficacy via Dendritic Cells and Flavivirus Vectors; Associate Professor of Clinical Investigation, Cellular Physiology and Immunology, The Rockefeller University

Vector-based Control of Transmission: Discovery Research Mosquito-borne diseases kill millions of people

promising Grand Challenges in Global Health

every year. Despite recent gains in its control,

research into depleting and/or incapacitating

malaria remains the biggest killer; at the same

disease-transmitting mosquitoes. It has three

time the incidence of dengue is increasing

areas of focus:

dramatically around the world. Absent effective vaccines, prevention strategies have focused largely on controlling mosquito populations and inhibiting disease transmission to humans. However, as mosquitoes develop resistance to insecticides, existing approaches are not enough.

Cost-effective and long-lasting biological control methods • In 2011, researchers at Imperial College London and the University of Washington, Seattle, made a groundbreaking advance toward a genetic control measure for

Funded by the Bill & Melinda Gates Foundation,

mosquitoes that transmit malaria. They

the Vector-based Control of Transmission:

demonstrated that by inserting the gene for

Discovery Research (VCTR) initiative is

a particular enzyme into a few mosquitoes

managed by the FNIH. It builds on the

and allowing them to mate with standard (continued on page 12)

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 11


and Forward

Vector-based Control of Transmission: Discovery Research (continued from page 11)

mosquitoes, the gene rapidly spreads

unique molecular components of insect

throughout an entire laboratory-confined

odorant receptors (ORs). After isolating

population. Their next step is to configure

and cloning the genes that encode

the enzyme to inhibit the mosquitoes’ ability

these ORs, they have expressed them in

to reproduce, which would result in fewer

mammalian cells. This allows for the facile

offspring with each successive generation.

screening of hundreds of thousands of

• Researchers at the University of Queensland, Australia, completed a successful first-round of field trials on a biocontrol agent aimed at eliminating dengue transmission. The Wolbachia bacterium inhibits dengue virus development within the mosquito, and Wolbachia-infected female mosquitoes readily transmit the bacterium to their progeny, so the entire mosquito population should become incapable of harboring and spreading dengue. The team confirmed that Aedes

chemical compounds to identify which ones can activate or inhibit the receptors. These activators and inhibitors become the starting point for the development of new odorant-based products to reduce disease transmission by mosquitoes and to control other agricultural insect pests. Already, a number of the compounds identified have been found to be effective at concentrations 1,000 times lower than that observed with DEET, the most widely used insect repellent.

mosquitoes infected with dengue-inhibiting Wolbachia quickly became established in two locations in northeastern Australia. Second-stage trials are underway with the latest wet season. Repellents or attractants that exploit or disrupt the mosquito’s odor receptors • Specific odor cues emanating from people help mosquitoes locate them for

“The Gates-FNIH funding has been absolutely essential, for it has afforded the opportunity for us to take observations in basic neural science and think about the implications of those observations for the eradication of

a blood meal. Yet, some people are much

insect-borne human disease. Without this

more attractive to mosquitoes than others.

funding, we would not have the capability

Investigators at the Wageningen University

of moving our research in that direction.

in the Netherlands and at the University of Colorado, Boulder, showed that the

The FNIH leadership has been absolutely

difference is associated with the kinds

seminal in providing their expertise

of bacteria that reside on an individual’s skin. Further study should aid in the development of new mosquito repellents. • Teams headed by Larry Zwiebel of Vanderbilt University and by Richard Axel of Columbia University have identified

in insect-borne disease, leading us scientifically in the right direction, and in establishing collaborative partnerships. Put simply—they’ve been great.” Richard Axel, M.D. VCTR Investigator; Professor, Howard Hughes Medical Institute, Columbia University; and 2004 Nobel Prize winner in Physiology or Medicine

12 | 2 0 1 1 A N N U A L R E P O R T


Safer, more effective, and less expensive insecticides Current commercially available insecticides target a very small number of biological mechanisms in the mosquito. Some compounds are toxic to humans and are damaging to the environment; only one class of compounds—pyrethroids—is approved for use in treating bed nets. Emerging resistance to pyrethroids threatens this lifesaving control measure.

“What has been different about our relationship with the FNIH compared to other funders is their active involvement in our research program. They’ve contributed to different issues and helped us focus our attention on key issues. They’ve proven to be invaluable over the last few years.” SCOTT O’NEILL, Ph.D. Project Leader, Eliminate Dengue project and Faculty of Science Dean, Monash University, Victoria, Australia

• Jeffrey R. Bloomquist, of the University of Florida, will interfere with the voltagesensitive potassium channel—an important component of the mosquito’s nervous system—to develop a new mosquitocide. • Robert M. Kennedy, of the Vestaron Corp., in Kalamazoo, Michigan, will develop small To address the urgent need for new insecticides with novel modes of action, the FNIH issued

molecule inhibitors that mimic the properties of toxic peptides found in spiders.

a call for research proposals in this area. After

• Peter M. Piermarini, of The Ohio State

a very competitive review process, it awarded

University, will use high-throughput

grants to four projects in 2011:

technology to discover chemicals that

• Barry Beaty, of Colorado State University, will utilize nanotechnology to formulate and deliver

induce “kidney” failure in the malaria vector Anopheles gambiae.

insecticidal compounds to the mosquito.

Expression of a blue fluorescent protein in tissues of the malaria vector mosquito, Anopheles stephensi. Used by permission N. Xavier, J-M. Sandoval and A.A. James (see Nirmala et al., 2006, Insect. Biochem. Molec. Biol., 36, 694-700. PMID: 16935218).

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 13


and Forward

Identification of High-quality HITs for Tuberculosis The HIT-TB project, launched in 2010, is an

tuberculosis bacteria using a chemical library

FNIH partnership with the Bill & Melinda Gates

of diverse, high-quality molecules. The goal is

Foundation and the National Institute of Allergy

to identify a series of well-characterized small

and Infectious Diseases, along with the

molecules with defined, tractable bacterial

Universities of Cape Town, Cambridge and

targets, which potentially could be developed

Dundee. Negotiations are underway with potential

into drugs against tuberculosis. In its first year,

additional pharmaceutical company partners.

the project made advances in progressing and

This project supports high-throughput screening of whole Mycobacterium

evaluating several HIT series of high interest from earlier screens.

Malnutrition and Enteric Diseases Network The Malnutrition and Enteric Diseases Network

periods in early life, and with this knowledge

(MAL-ED) project, launched in late 2008, is an

design better intervention strategies to limit

FNIH partnership with the Bill & Melinda Gates

the risk of mortality and morbidity in children.

Foundation and is co-led by the NIH’s Fogarty

Approximately 2,000 children have been

International Center and FNIH. MAL-ED supports

enrolled at birth and are being closely followed

a number of U.S. academic and internationally

until at least two years of age.

based institutions and the U.S. and Thai militaries to form a network of eight field sites in the developing world that focus on populations with high levels of malnutrition and enteric infections.

The network is part of a consortium of affiliated Gates Foundation-funded projects. Although these projects are not directly managed by

MAL-ED seeks to improve understanding of the complex interrelationship between enteric infections and malnutrition and to describe its compounding effects on growth, on immune responsiveness to orally administered vaccines and on cognitive development in young children in resource-poor environments. One of the project goals is to identify vulnerable

2006

The FNIH launches the Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC), with a grant from the Bill & Melinda Gates Foundation. See page 7.

The FNIH launches the Genetic Association Information Network (GAIN), a partnership with the National Human Genome Research Institute, Pfizer, Affymetrix, the Broad Institute and other private donors. GAIN was designed to identify the genetic polymorphisms associated with common diseases by conducting genomic studies and making results available to researchers worldwide. The program’s protocols for protecting participant privacy and confidentiality have served as a model for similar studies across the scientific community.

14 | 2 0 1 1 A N N U A L R E P O R T

The FNIH launches the Biomarkers Consortium, its first partnership aimed at improving clinical and regulatory science, with the NIH, FDA and PhRMA. The Consortium will grow to include a diverse set of projects to qualify biomarkers for use in drug development and clinical care, and attract more than 40 partners from government, industry, academia and nonprofit groups. See page 5.

The FNIH and the National Institute of Mental Health (NIMH) launch the Schizophrenia Metabolic Initiative to evaluate the effects of switching antipsychotic medications to reduce the risk of cardiovascular disease among individuals with schizophrenia.

The FNIH initiates the Biotechnology Resource for Innovation and Development in Genomedicine project, with support from the Avon Foundation and private philanthropists.


the FNIH, they benefit from collaborating with MAL-ED investigators and by having access

“The FNIH and [The Bill & Melinda] Gates

to MAL-ED resources, data and samples.

[Foundation] support has made possible

These companion projects seek to identify genetic markers of susceptibility to childhood

the multicenter study of the suspected

malnutrition, to establish the role of the gut

profound lasting effects of early

microbiome in malnutrition and susceptibility to

childhood diarrhea and enteric infections

enteric infection, and to identify factors involved

(with or without diarrhea). It has engaged

in children’s poor immune responsiveness

top institutions from Asia, Africa and

to oral polio and rotavirus vaccines in the

Latin America and innovative,

developing world.

state-of-the-art molecular and field

In 2011, the FNIH received supplemental

assessments to assess these

funding from the Bill & Melinda Gates Foundation to participate in additional

lasting effects of intestinal

sample and data collection for a recently

infections in the first … years of life

awarded companion project. The aim is

on children’s physical growth and

to determine the effects of the mother’s

cognitive development.”

microbiome on her child’s endogenous microbial and physiological development. That project

RICHARD L. GUERRANT, M.D.

is contributing to a research pipeline for the

Thomas H. Hunter Professor of International Medicine, Director, Center for Global Health, University of Virginia

development of protective probiotics. The Bill & Melinda Gates Foundation also provided a grant that enabled the FNIH to organize an international workshop on the important yet overlooked enteric parasite Cryptosporidium. The workshop featured updates on the global burden of this infection, and on diagnostics and therapeutics, and has provided a

2007

useful framework for future research directions.

The FNIH hosts the first Collaborative Summit on Breast Cancer Research in partnership with the Avon Foundation, the American Association for Cancer Research, the American Cancer Society, The ASCO Foundation, The Breast Cancer Research Foundation, the National Breast Cancer Coalition Fund, the Polo Ralph Lauren Foundation/Pink Pony, Susan G. Komen for the Cure and the National Cancer Institute.

CRTP holds a 10-year reunion, gathering graduates of the program and their former tutors and mentors on the NIH campus for a two-day workshop and celebration.

The first O’Neill Fellow makes an important discovery in genetic mechanisms found in 50 percent of all kidney cancer patients. This discovery, made by Dr. Nanae Harashima and the team of doctors in Dr. Richard Childs’ lab, leads to new treatments to stem the cancer’s spread and gives new hope for a cure.

Foundation for the National Institutes of Health

ADNI completes enrollment of 823 participants and begins collecting and analyzing data.

The FNIH receives its first four-star rating from Charity Navigator and is also named to the top 400 Charities List by the Chronicles of Philanthropy. It receives both honors again in 2008, 2009, 2010 and 2011.

W W W . F NIH . OR G | 15


and Forward

Alzheimer’s Disease Neuroimaging Initiative Eight years after its initial launch, the

and other biomarker tests and measures used

Alzheimer’s Disease Neuroimaging Initiative

to track disease progression over time. Next,

(ADNI) has produced numerous adjunct and

it created an open database, where data could

follow-up studies that are not only advancing

be uploaded and downloaded as they were

understanding of this devastating disease,

generated. This enabled researchers around the

but changing the way scientific research is

world to access, share and compare data and

conducted worldwide. The program was conceived by the National Institute on Aging which provides the public support, and the FNIH providing support

“With its unique ability to creatively

from the private partners, with the goal of

connect private and public-sector

encouraging collaboration by a wide array

institutions, the Foundation for the

of researchers in academia and industry.

NIH has been an essential partner in

To do that, the initiative had to first solve the problem of standardizing collection of different types of research data. It established detailed protocols for enrolling patients in the study and for collecting and assessing the clinical/ neuropsychological, neuroimaging,

16 | 2 0 1 1 A N N U A L R E P O R T

this important initiative.” NEIL BUCKHOLTZ, Ph.D. Chief, Dementias of Aging Branch, Division of Neuroscience, National Institute on Aging


“Although it may not have been fully appreciated initially, the degree of academic, government and industry findings quickly, even before publication

engagement in ADNI paved the way for

of papers. The net effect is a significant

the principle of a successful

acceleration of critical, and otherwise

precompetitive consortium. ADNI

expensive, research. The model’s success has won over skeptics,

brought together a number of AD investigators and industry leaders, all in

attracting additional funding and participation.

strong support of its overall concept and

As a result, the launch of ADNI 2 is enabling

goals. In hindsight, it is remarkable to note

researchers to: • track the study’s initial control and mild cognitively impaired patients for another five years; • enroll 1,200 new individuals, some of who present with early mild cognitive impairment; and • add new imaging techniques for detecting the progression of Alzheimer’s disease. Because of the success of ADNI, and through

how potential competitors in the pursuit to develop drugs for AD joined forces and are now committed cooperators together with academic centers, under the auspices of NIA and the FNIH. When ADNI now, after eight years, has completed ADNI 1 and is now well into ADNI 2, through the stepping stone of the ADNI-GO grant, one can not only reflect

the efforts of the Alzheimer’s Association,

on the value of ADNI as a critical effort to

ADNI is becoming a worldwide initiative with

better understand AD pathophysiology

programs utilizing the standards and protocols

and the progression of this devastating

developed here. Initiatives are currently

disease, but also on the fundamental

ongoing in Denmark, France, Germany, Italy, the Netherlands and Sweden through

importance ADNI has on the design of

European ADNI; from Japan through J-ADNI;

innovative therapy trials. Although the

from Australia through the Australian ADNI;

outcome of current industrial efforts

from South Korea through K-ADNI; and from

remains unclear, ADNI provides a critical

Taiwan through TW-ADNI. Argentina, China and Thailand are in the discussion stages of joining World Wide ADNI. Together, these efforts are

scientific platform for the execution of such endeavors, and by this brings hope

creating a substantial dataset no one entity

to patients and caregivers that better

could amass on its own, and, thanks to its

treatment options will emerge.”

open nature, a legion of scientists working to decipher its clues.

JOHAN LUTHMAN, D.D.S., Ph.D. Chair, ADNI 2 Private-Partner Scientific Board; Senior Program Leader, Neuroscience & Ophthalmology R&D, Franchise Integrator, Merck & Co.

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 17


and Forward

SubPopulations and InteRmediate Outcome Measures in COPD Study While the incidence of Chronic Obstructive Pulmonary Disease (COPD) is increasing sharply in the U.S., a cure remains out of reach for this progressive and debilitating condition. The SubPopulations and InteRmediate Outcome

“The concept at NHLBI was to engage the Foundation for the NIH to in turn engage

Measures in COPD Study (SPIROMICS) is laying

private industry. In fact, private industry is

the groundwork for clinical trials that could

now extremely enthusiastic about this

speed development of effective therapies.

project, as is the FDA.

Supported by the FNIH and six private sector

The FDA said it specifically wanted more

partners, National Heart, Lung and Blood Institute is collecting and pooling lung function,

information about a certain aspect—

imaging and biochemical data from more than

COPD exacerbations. So we revised the

3,000 COPD sufferers and controls over three

protocol with input from the FDA and

years. These data will allow scientists to better

industry partners, and now it’s a much

categorize patients according to their specific COPD profile, which in turn should help them tailor potential therapies to those most likely

better protocol, scientifically, as a result. And industry partners can easily see the

to benefit.

added value of doing these experiments.

At the same time, researchers will scrutinize the

This absolutely would not have been

data to identify more precise measures of the

possible without the Foundation for the

disease’s progression. This will enable them to more quickly assess whether an experimental therapy is working. The study is being conducted over seven years at six academic clinical centers across the United States.

NIH—they created the forum for discussion among all sectors, which actually is the most important thing. And they brought in the financial contributions.” STEPHEN RENNARD, M.D. Chair, SPIROMICS Steering Committee; Larson Professor of Medicine, University of Nebraska Medical Center

18 | 2 0 1 1 A N N U A L R E P O R T


Human Papilloma Virus Clinical Trial The National Cancer Institute (NCI) HPV-16/18 Vaccine Phase 3 Trial in Costa Rica completed four years of follow-up on its 7,466 randomized participants in 2011. Results from the trial indicated high efficacy of the vaccine against new infections with human papilloma virus (HPV) types included in the vaccine and partial protection against new infections caused by several other HPV types (types 31, 33 and 45) that are closely related to HPV-16/18. HPV is the most common sexually transmitted infection, and HPV-16/18 is responsible for an estimated 70 percent to 80 percent of all cases of cervical cancer worldwide.

health as they grow older. Altogether, the $28 million partnership is funding 17 different research projects over the course of five years.

The vaccine used in the Costa Rica trial was manufactured by GlaxoSmithKline (GSK) Biologicals. With an infusion of $6 million in additional funding via the FNIH, investigators at NCI were able to ensure that validation and regulatory aspects of the trial were incorporated so that the data could be included as part of the FDA Investigational New Drug (IND) held by GSK Biologicals. Submission of the final IND report is pending.

Neuro-Oncology Branch Fund Despite important advances in imaging, neurosurgery and radiation, the prognosis for patients with the most common type of primary brain tumor has improved very little over the past 20 years. Most patients survive less than a year after diagnosis. A joint program of the National Cancer Institute and the National Institute of Neurological Disorders and Stroke,

Funding such programs is an important way

the Neuro-Oncology Branch was established

the FNIH helps translate scientific research and

to develop a new, nontraditional approach to

development into real health improvements in

fighting primary brain and central nervous

people’s lives.

system cancer.

Research Partnership in Cognitive Aging Scientists throughout the country met in October 2011 to discuss their latest findings on changes in brain function and behavior associated with normal aging. The researchers are grant recipients from the Research Partnership in Cognitive Aging, an FNIH initiative with the National Institute on Aging and the McKnight Brain Research Foundation. The program aims to expand understanding of how people think, learn and remember with age, and to develop interventions to maintain cognitive

Foundation for the National Institutes of Health

In 2011, the FNIH launched its Neuro-Oncology Branch Fund to support this effort, which focuses on biology-driven, individualized therapeutics. Centralizing patient care has enabled the branch to amass a vast tissue database for laboratory research and a large patient population from which to draw for clinical trials. The branch also hosts one of the few neuro-oncology fellowship-training programs in the United States. Already the branch has made notable strides, including the activation of 11 clinical trials and the identification of a dozen compounds worthy of clinical testing.

W W W . F NIH . OR G | 19


and Forward

Training and Education

20 | 2 0 1 1 ANNUAL RE P ORT


Just as vital as fundamental laboratory work in advancing biomedicine, training and education programs must be robust and accessible to equip and inspire the next generation of young scientists. Through its support of lectures, coursework, internships, fellowships, residencies and scholarships, the FNIH helps to ensure that the progress of biomedical research continues apace. The FNIH funding often can expand substantially the reach of training programs by affording videoconference and remote-site linkages. The Bernard Osher Foundation/ NCCAM Complementary and Alternative Medicine Practitioner Research Career Development Award In partnership with the National Center for Complementary and Alternative Medicine (NCCAM) at the NIH, the Osher Foundation provides support for NCCAM fellowships to individuals studying complementary and alternative medicine. Through this program, established in 2006, awardees receive up to five years of intensive, supervised career development research training in biomedical, behavioral or clinical sciences related to complementary and alternative medicine.

Principles of Clinical Pharmacology Through a partnership established in 2008, the PhRMA Foundation helps to broaden the reach of the NIH’s Principles of Clinical Pharmacology course. The course fills a significant void, as most medical

The course teaches the pharmacologic aspects of drug development and use in therapeutics, preparing trainees for the certification exam of the American Board of Clinical Pharmacology.

Sayer Vision Research Lecture Napoleone Ferrara, M.D., Ph.D., a Fellow at Genentech, Inc., delivered the fifth Sayer Vision Research Lecture at the NIH in June 2011. Ferrara’s address was entitled, “Basic Science and Clinical Application of VEGF.” Early in his career, Ferrara played a key role in isolating and cloning vascular endothelial growth factor (VEGF), a protein that stimulates formation of new blood vessels. He identified the protein’s role in abnormal vessel growth in eye diseases such as wet age-related macular degeneration (AMD), a leading cause of vision loss in older Americans. Building on that research, his laboratory developed an anti-VEGF

schools do not offer a formal course in this field.

antibody fragment, which can significantly improve

The lecture series, which runs from September

loss. This work earned him the 2010 Lasker-DeBakey

through April, is taught by faculty from the NIH, the

Clinical Medical Research Award—one of the most

FDA, the pharmaceutical industry and academic

prestigious awards in science.

institutions across the country. In 2011, the course attracted a record 1,196 students—physicians, pharmacists and other scientists. About a third

sight in wet AMD patients and limit further vision

The Sayer Lecture is supported by the Sayer Vision Research Fund at the FNIH. See page 33.

attended the lectures at the NIH campus, with the rest participating via teleconference from 24 remote sites in the U.S. and abroad.

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 21


and Forward

Clinical Research Training Course Modeled after a long-running course at the NIH Clinical Center, the first Clinical Research Training Course was held at the Kulakov Federal Research Center for

“The Laboratory Animal Medicine

Obstetrics, Gynecology and Perinatology in Moscow in

Residency Training Program is an exciting

November. A component of the U.S.-Russia Scientific

opportunity for me. It has allowed me to

Forum, the course was taught by Clinical Center

explore the world of laboratory animal

Director John I. Gallin, M.D., and other NIH faculty.

medicine and biomedical research.

Entitled “Principles and Practice in Clinical Research,”

Currently, I am in my clinical rotations

the five-day course featured lectures on clinical trial

and I have enjoyed the challenges of

best practices, orphan and rare diseases, ethics,

keeping my ‘patients’ healthy and happy.

research integrity, data safety monitoring, data analysis and more. The approximately 220 Russian

My mentors have provided me the

participants were chosen from a broad range of

opportunity to understand and improve

medical specialties.

the health and welfare of my animal

Planning is underway for the year two course,

patients, while supporting investigators

which will focus on pharmacology.

with the best research opportunity.

Laboratory Animal Medicine Resident Training Program

After successful completion of this

The NIH, through the Division of Veterinary Resources and the National Heart, Lung and Blood Institute, has developed the Laboratory

residency, I hope to join the ranks of ACLAM (American College of Laboratory Animal Medicine) board-qualified

Animal Medicine Resident Training Program.

veterinarians and support the

This program prepares laboratory animal

advancement of biomedical research

veterinarians and develops a resource of specially trained laboratory animal veterinarians for the NIH intramural research program as well as the entire laboratory animal and research community. Thanks in part to SoBran and its generous contribution, the program has enrolled its first resident trainee, Tannia Clark, D.V.M. Clark is currently participating in a multi-disciplinary rotation over the course of two years, including didactic training classes, exposure to the mouse imaging facility, study of the laws and regulations of animal research and development of a research project. This training will prepare Dr. Clark for the certification examination for the American College of Laboratory Animal Medicine.

22 | 2 0 1 1 A N N U A L R E P O R T

with a continued emphasis on animal welfare.” TANNIA CLARK, D.V.M. Laboratory Animal Medicine Resident, National Institutes of Health


“I remember the moment I was awarded

Furthermore, these skills directly prepare me

the Newcomb scholarship, the grant that

for future career aspirations: namely,

would allow me to work in a cutting-edge

medical school and beyond.

neuroendocrinology lab at the National Institutes of Health. After jumping up and down appropriately, I called my parents, mentors and extended family to share the news. Everyone, like me, was excited and awed—it was a dream come true. I uprooted myself from my Pacific Northwest home and trekked out to Washington, D.C., to embark on this grand adventure. Ultimately, the shift from thinking like a college student to thinking like a scientist has been challenging, rewarding and truly

First and foremost, researching at the National Institutes of Health has confirmed that this is the career for me. I’m deepening my abilities as a scientist, my respect for the community, and the confidence to continue as a professional. To be given the opportunity to live in such an exciting place and to develop as a researcher is truly remarkable: I try to take advantage of every second.” SARAH SHANGRAW 2011–2012 Robert Whitney Newcomb Fellow

meaningful. I am actually doing science, not just learning about it in a classroom.

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 23


and Forward

Other Programs “A major component of the Clinical

ADAS Cog

Center’s vision is to lead the global effort in training today’s investigators. Through a generous donation to the Foundation for the NIH from Eli

Age-Related Eye Disease Study Genetic Repository Toxicity Study of Buprenorphine/Naloxone Burkitt Lymphoma Genome Sequencing Project Congenital Adrenal Hyperplasia

Lilly, we were able to offer the

Cancer Research Fund

Clinical Center’s “Introduction

Clinical Investigator Student Training Forum

to the Principles and Practice of

Clayton-Dedonder Scholarship Awards

Clinical Research” course in

Clinical Center In-Kind Drug Donation Program

Moscow for the first time in

Drug Induced Liver Injury Network

November 2011. About 220 students participated in the course, which was

Epigenetic and Immunoregulatory Control of Ocular Inflammatory Disease Evaluation of the Effect of Negative Costimulatory Signals on the Model of Experimental Autoimmune Uveitis Using the Ig Fusion Construct AMP-110

presented at the Kulakov Federal Research Center for Obstetrics, Gynecology and Perinatology in Moscow. A second course, “Principles

Development and Production of Endotoxin under GMP for Human Clinical Research

of Clinical Pharmacology,” will be

Frequent Hemodialysis Project

offered in Moscow in 2013. FNIH

Google Ad Grant for Parkinson’s Disease Research

support is allowing us to have both

Hereditary Hyperhomocysteinemia

textbooks translated into Russian,

Human Genome Exhibition

which will be a tremendous resource

Human Microbiome Project Demonstration Projects

for our colleagues there.”

I Can Do It, You Can Do It

JOHN I. GALLIN, M.D.

The Observational Medical Outcomes Partnership (OMOP) begins. The first project of its kind, OMOP conducts methodological research for active safety surveillance of drugs already on the market. See page 9.

24 | 2 0 1 1 A N N U A L R E P O R T

With initial funding from Diet Coke, the FNIH establishes The Heart Truth® Community Action Program in partnership with the NHLBI to promote women’s heart health.

The FNIH receives a grant from the Bill & Melinda Gates Foundation to establish the Malnutrition and Enteric Diseases Network (MAL-ED). See page 14.

GAIN ends, having mapped the genotypes and phenotypes of 18,000 samples and posts them to the National Library of Medicine database of Genotypes and Phenotypes.

2009

The first Cognitive Aging Summit takes place with support from the McKnight Brain Research Foundation and NIA. The summit identifies recommendations for research directions, ultimately leading to the Research Partnership in Cognitive Aging. The partnership, coordinated by the FNIH, funds 17 research grants totaling $28 million. See page 19.

2008

2007

Director, Clinical Center, National Institutes of Health

The FNIH hosts the inaugural mHealth Summit. See page 27.


Other Programs (continued from page 24)

Schizophrenia Metabolic Initiative

Induced Pluripotent Stem Cell Consortia

Senior Independent Living Research Network

Measures for Clinical Trials of Treatment of Cognitive Impairment

Smoldering Multiple Myeloma

Mutational Analysis of the Melanoma Genome

T Regulatory Cells as a Peripheral Marker for the Development of Age-Related Macular Degeneration and Uveitis

Neurotropin Research Project NIH Medical Research Scholars Program

T-Cells & AMD

Oxford-Cambridge Scholarship Program

Tracking Intracellular Nanoparticle Dynamics and Cytotoxic/Epigenetic Signatures both in vitro and in vivo Using Advanced Cytometry and Multimodal Imaging

Oxford-Cambridge Colloquium

Undiagnosed Diseases Program

Pain and Palliative Care Program, Roxane Institute

Vaccine Research Center’s Community Advisory Board

Osteoarthritis Initiative 2 Overcoming Barriers to Early Phase Clinical Trials

PATH: Physical/Psychological Advocacy & Treatment for HIV Youth Program Pew Latin American Fellows Partnership Post-doctoral Fellowship in Molecular Imaging and Nanomedicine Progressive Multifocal Leukoencephalopathy Data Registry

Celebrities Bill and Giuliana Rancic participate in the 4th Annual Boo! Run For Life 10K run and two-mile Tidal Basin walk in Washington, D.C., to raise awareness and funds for kidney cancer research. The event is organized by friends and family of Dean R. O’Neill.

The FNIH receives a grant from the CVS Caremark Charitable Trust to establish the I Can Do It, You Can Do It community grant program to promote physical fitness for children with disabilities.

The FNIH receives grants from the Bill & Melinda Gates Foundation for the Vectorbased Control of Transmission: Discovery Research initiative and the Centralized Envelope Comparative Immunogenicity Phase I Trial. See pages 8 and 11.

Results of the Biomarkers Consortium’s first completed project—that a protein, adiponectin, is a predictive marker for Type 2 diabetes —are published in Clinical Pharmacology and Therapeutics.

Foundation for the National Institutes of Health

The MAL-ED project establishes harmonized protocols and begins enrolling infants into the study at eight sites in Africa, Asia and South America.

The FNIH awards the first The Heart Truth® Community Action Program grants. See page 28.

2010

Edmond J. Safra Family Lodge

The FNIH introduces new brand.

The FNIH partners with pharmaceutical companies to secure in-kind drugs for the NIH Clinical Center pharmacy.

W W W . F NIH . OR G | 25


Events

Beyond the conferences and symposia that are the workhorses of scientific information transfer, events have come to play a vital role in biomedical research—attracting nontraditional partners and funders to research initiatives and engaging the public in disease and health awareness. Acknowledging the power of networking and dialog in its various forms, the FNIH supports all manner of events, from career fairs to exhibits, receptions and media opportunities.

26 | 2 0 1 1 A N N U A L R E P O R T


mHealth Summit December 5–7, 2011, Washington, D.C. In many ways, the mHealth Summit is emblematic of the work of the FNIH as a whole. Inaugurated in 2009, the summit was conceived as a vehicle to converge two complex and fast-changing industries— medical science and telecommunications—to improve and even revolutionize health care delivery worldwide. To truly tap the potential of this alliance, the FNIH and its mHealth founding partners brought together not only scientists and technology experts, but entrepreneurs, scholars, practitioners, policymakers and others to map the new future of public health care. With the mHealth field still in its infancy, the first summit sparked immediate interest and enthusiasm, attracting 800 attendees from 25 countries. In the two years since, it has grown dramatically—bringing thousands of attendees, hundreds of exhibiting companies, visionary leaders such as Bill Gates and Ted Turner, and workable, on-the-ground solutions to health care delivery.

mhealth summit | Annual Growth

In 2011, the summit moved to Washington, D.C.’s

3600

Gaylord National Resort and Convention Center to accommodate the burgeoning crowd, exhibitors and

700

pavilions. In addition to super and special sessions, it offered 14 education tracks in the areas of business, policy, research, technology, mFinance and end-

2400

7

16

user solutions. Keynote speakers over the four

19

days included U.S. Secretary of Health and Human ORGANIZING PARTNERS

2009 SPONSORS

2010 Attendees

2011

Sponsors

Services Kathleen Sebelius, Qualcomm Chairman and CEO Paul E. Jacobs and Federal Communications Commission Chairman Julius Genachowski. The mHealth Summit has become the defining event for this fast-paced industry, and continues to grow in scope and sophistication. As producer, the FNIH is helping to vastly accelerate the pace of delivering quality, cost-effective health care to even the most remote corners of the world.

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 27


and Forward

The Heart Truth Red Dress Collection Fashion Show 2011 ®

February 9, 2011, New York, New York Each February since its launch, The Red Dress symbol has come to life on the runway with the support of the fashion industry and celebrity models at the Red Dress Collection Fashion Show.

Wheaton Franciscan-St. Joseph in Glendale, Wisconsin hosts a chef demonstration featuring heart healthy cooking.

This high-profile event at the Mercedes Benz Fashion Week is a signature part of The Heart Truth® campaign, an initiative of the National Heart, Lung and Blood Institute of the NIH. For the past decade,

“The Heart Truth grant made it possible for Wheaton Franciscan-St. Joseph to provide community outreach and education on women and heart disease to African American women and the impact was tremendous. Through our grant-supported efforts, we armed women with heart disease facts and

Photo courtesy of The Heart Truth’s Red Dress Collection

it has raised awareness of heart disease as the number-one killer of women in America. The

they took action for self-improvement by getting the recommended

campaign’s symbol is the Red Dress. Since

health care screenings, eating

2008, the Foundation for the NIH has helped

healthier and increasing their

spread The Heart Truth® message through its support of this event, as well as fund a community action program which awards grants to organizations across the country promoting women’s heart health. In 2011, the FNIH awarded grants totaling $200,000 to seven organizations, targeted especially at minority and underserved communities. Initiatives include free health screenings; activities promoting stress reduction, nutrition, exercise and emotional health; interactive websites; and training for outreach volunteers. SPONSORS

28 | 2 0 1 1 A N N U A L R E P O R T

physical activity.” ROSHA L. HAMILTON, R.N., M.S.W. Director Community and Patient Health Education Services, WheatonDirect Wheaton Franciscan Healthcare, Glendale, Wisconsin


International Human Microbiome Congress March 9–11, 2011, Vancouver, British Columbia Attention is increasingly being focused on the human microbiome—the microbial species that reside on and within the human body—as a means

National Institute of Arthritis and Musculoskeletal and Skin Diseases 25th Anniversary Scientific Symposium—Improving Lives Through Discovery June 13, 2011, Bethesda, Maryland

to understanding health and disease. This meeting,

NIAMS used the occasion of its 25th anniversary to

organized by the FNIH, attracted more than 400

host a symposium highlighting its accomplishments,

participants worldwide. Researchers from the

challenges and future direction. It attracted a wide

medical, microbial and computational fields convened

range of stakeholders—including the scientific

to discuss the complex relationships between the

community, volunteer and professional organizations,

microbiome and the human body, and were joined

patients and congressional staff—to address the

by food and pharmaceutical industry representatives,

scientific advances and the improvement to patients’

science reporters and funders.

lives made possible with NIAMS support.

The congress explored not only current findings

The symposium, supported by the FNIH, featured

in the field, but also ethical, legal and social

a broad array of presentations—scientific sessions

implications of the research and new technologies

from outstanding junior and senior researchers,

and computational tools to aid in the study.

reflections on the importance of mentors and training, and inspirational patient testimonials on how

SPONSORS

such research has affected their lives and families. A dinner presentation, “Bringing Medicine and Science to the Public,” featured National Public Radio host Diane Rehm. SPONSORS Saving You Time For Life

The Honorable John and Amy Porter

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 29


and Forward

JAK-STAT Pathway: Twenty Years from Discovery to Drugs

U.S.-Russia Collaboration in the Biomedical Sciences—Forum Meeting

September 22–24, 2011, Bethesda, Maryland

November 16–18, 2011, Moscow, Russia

Discovered 20 years ago, the JAK-STAT pathway is

Organized by the FNIH at the behest of the U.S.-

a complex biochemical mechanism for transmitting

Russia Bi-Lateral Presidential Commission, this

information across a cell membrane and into the

high-level forum was designed to encourage broader

nucleus to spur various activities. This pathway has

collaboration in biomedical and behavioral research

shed light on a number of diseases—from immune

between the two countries. Partners included the

deficiencies to hematological malignancies—and

NIH, the Institute of Medicine, the Russian Academy

the NIH holds the patent for exploiting it in search of

of Medical Sciences and the Russian Academy of

new immunosuppressive agents.

Sciences.

Many pharmaceutical firms have since targeted

The three-day meeting featured distinguished

this pathway in their efforts to develop a new class

researchers from the United States and the Russian

of drugs. This meeting, organized by the FNIH,

Federation and focused around five agendas: cancer,

brought together industry scientists to present their

active and healthy lifestyles, human development, rare

most recent work and to spotlight the translational

diseases and infectious diseases. A complementary

advances that have been made.

meeting, concerning brain sciences, was held at the

SPONSORS

NIH campus in Bethesda, Maryland. FOUNDING PARTNER

SPONSORS

Marvin Hamlisch in Performance at the Family Lodge Cheerful music brought joy to scores of patients, families and staff at the NIH Clinical Center on December 20, 2011. For the seventh year in a row, acclaimed composer Marvin Hamlisch delighted guests at a holiday concert held on the NIH campus. He was joined this year by Broadway actor and vocalist Gary Mauer. Each year, Hamlisch performs at the NIH as a tribute to his friend Lily Safra and her late husband Edmond. Mrs. Safra is a longtime benefactor to patients and their families undergoing treatment at the Clinical Center, having provided the leadership gift to the FNIH to build the Edmond J. Safra Family Lodge on the NIH grounds.

30 | 2 0 1 1 A N N U A L R E P O R T


Ecology and Evolution of Infectious Diseases

4th Annual NIH Graduate and Professional School Fair

March 26–29, 2011

July 22, 2011

Sponsor

Sponsor

U.S.-Russia Forum Planning Meeting

NINR—Science of Compassion— End of Life Symposium

April 24–25, 2011 Sponsors

August 10–12, 2011 Sponsor

4th Annual NIH Career Symposium May 10, 2011

NHLBI Genomics Symposium September 12–13, 2011 Sponsor

Sponsor

NINR-NIH Clinical Center Joint Conference May 12, 2011

NIH Director’s Pioneer Award Symposium and Award Reception September 20, 2011 Sponsors

Sponsor

Alzheimer’s/Dementia Outcome Measures Meeting May 24, 2011 Sponsors

Symposium on Cardiovascular Regenerative Medicine October 4–5, 2011 Sponsors

NIH/FDA Glycosciences Research Day June 15, 2011 Sponsors

NINR Concluding Scientific Symposium October 13, 2011 Sponsor

NCMRR 20th Anniversary Symposium December 12–13, 2011 Sponsors

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 31


and Forward

Funds and endowments established at the FNIH are a lasting way for individuals and organizations to pay tribute to special people or causes through ongoing support of research, education or events in biomedicine at the NIH. Large or small, such gifts are a testament to the impact every person can make on discoveries that advance human health.

32 | 2 0 1 1 A N N U A L R E P O R T


Funds and Endowments Named Funds

Memorial Funds

Named funds are created to support specific areas

Memorial funds create a living legacy. In many

of research or fellowships, lectures or awards at the

cases, a family member may request that friends

National Institutes of Health.

and relatives make donations—rather than send flowers—to support a chosen cause in memory of a

Gramlich Melanoma Research Fund

loved one. Families may wish to go one step further

The Gramlich Melanoma Research Fund supports

and establish a fund that embodies a loved one’s

melanoma research at the NIH through an annual gift

passion and spirit by making a significant investment

provided by the Jack Gramlich Foundation.

in the Foundation.

NIH Director’s Initiative Fund

Dr. John L. Barr Memorial Fund

Established in 2008 in honor of Dr. Elias Zerhouni,

The Dr. John L. Barr Memorial Fund helps to

who served as the NIH Director from May 2002

support the Intramural Research Training Award

through October 2008, the fund supports special

Fellowship Program at the NIH Clinical Center’s

initiatives of importance to current and future NIH

Pain and Palliative Care Service. The objective

Directors and scientists.

of the fellowship is to conduct research on pain and palliative care, and also to encourage young

Sayer Vision Research Fund

investigators to become more familiar with the

The Sayer Vision Research Fund supports an annual

importance of this field of study.

lecture delivered by an investigator in the area of vision research. The fund also supports the Sayer

Adam J. Berry Memorial Fund

Vision Research Award, a grant-in-aid to support the

The Adam J. Berry Memorial Fund was established

research of a promising independent investigator, in

by Michael and Sue Berry in memory of their

the early stage of his or her research career in the

beloved son, Adam. Adam came from Australia to

Division of Intramural Research at the National Eye

work as a research scientist at the National Cancer

Institute. The fund was established by NIH research

Institute. The fund commemorates his life and

scientist Jane Sayer, in honor of her family and in

his enthusiasm for work by making it possible for

memory of her parents, Winthrop and Laura Sayer.

promising young Australian scientists to travel to the United States and work at the NIH.

Swanson Family Fellowship in TTF-1 mutation-causing benign chorea in the

Edna Williams Curl and Myron R. Curl Fund for Multiple Sclerosis Research

laboratory of infectious diseases under the direction

The Edna Williams Curl and Myron R. Curl Fund,

of Steven M. Holland, M.D., Chief of the Laboratory of

established in 2007, supports multiple sclerosis

Clinical Infectious Diseases at the National Institute of

research at the National Institutes of Health.

The Swanson Family Fellowship supports research

Allergy and Infectious Diseases at the NIH.

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 33


and Forward

John Laws Decker Memorial Fund

Family and friends of the late Dean O’Neill

A former Director of the NIH Clinical Center,

established the fund. More information can be

Dr. John Laws Decker strived to connect

found at www.renalcellcancer.org. The family

research communications around the world to

also organizes the annual Boo! Run for Life 10K race

exchange information and accelerate important

and two-mile walk to support the fund. Information

scientific research. His dedication to education

about the Boo! Run, held annually in October, can

and communication about science led the NIH

be found at www.boorunforlife.com.

to establish an annual lecture in his name. This fund, established by the Decker family, supports

Dr. Edward T. Rancic Memorial Fund

a small event for the lecturer each year.

The Dr. Edward T. Rancic Memorial Fund supports a post-doctoral fellowship that focuses on renal

Dean R. O’Neill Renal Cell Cancer Research Fund

cell cancer research in the laboratory of tumor

The Dean R. O’Neill Renal Cell Cancer Research

the National Heart, Lung and Blood Institute. The

Fund supports a fellowship in the laboratory of

fellowship was established in memory of Dr. Edward

tumor immunology headed by Richard Childs, M.D.,

Rancic by his family. The 2011 Rancic-O’Neill Fellow

immunology headed by Richard Childs, M.D., of

was Quinn Weisman.

Dr. Anita Roberts Memorial Fund Dr. Roberts was one of the first female laboratory chiefs at the NIH and ranked in the top 50 mostcited biological scientists in the world. She was widely recognized as an outstanding mentor, encouraging and inspiring young scientists. In recognition of her commitment to mentoring, Dr. Roberts’ family and lab colleagues established scholarships to allow graduate students and postdoctoral fellows to present their work at a national of the National Heart, Lung and Blood Institute.

meeting. Two travel scholarships are awarded to

The postdoctoral cancer investigator funded by

the TGF-beta Keystone Symposium held every

the program conducts research on the treatment

other year. These scholarships are a fitting tribute

of renal cell (or kidney) cancer. The 2011 Rancic-

to Dr. Roberts’ passion for encouraging the career

O’Neill Fellow was Quinn Weisman.

development of young scientists.

If you are interested in establishing a fund or endowment at the FNIH, and making a significant investment and impact on a disease that is important to you or a loved one, please contact Caite Gilmore at 301-594-2612 or cgilmore@fnih.org.

34 | 2 0 1 1 A N N U A L R E P O R T


“The lodge is beautiful and it’s been amazing staying here. It was very inviting to walk into the lodge. It’s been the best place I have stayed.” “Everything was great. I am most grateful to have been a guest.” “The comfort. Being able to relax by the fire or sit and visit over coffee in the kitchen. And to be able to walk to the [Clinical Center].” Safra Lodge Guests

Tracy’s Toy Box

Over the course of two years, the Solarz’s friends

Established by the family in memory of Tracy

and family contributed more than $240,000 to

Nadel, the Tracy’s Toy Box Fund purchases toys and

support this important research in Steve’s memory.

activities for children staying at the Edmond J. Safra

In 2011, the Solarz Fund enabled Dr. Schrump to

Family Lodge. These items aim to help make their

begin research aimed at developing a cancer vaccine

time at the Lodge more comfortable and pleasant.

for all types of cancer. The fund supported research that manipulates DNA in cells taken from a patient’s

Robert Whitney Newcomb Memorial Fund

tumor to produce molecules that will stimulate the

The Robert Whitney Newcomb Memorial Fund

immune system to kill cancer cells. In this way, Dr.

was established by the family to remember Dr.

Schrump creates a vaccine from a patient’s own

Newcomb, who began his scientific career at the

tumor cells—a “personalized cancer vaccine.”

NIH as a high school summer intern in a laboratory at the National Cancer Institute. The fund endows an annual lecture by a recognized expert in neuroscience, selected by the National Institute of Neurological Disorders and Stroke (NINDS). Honoring Dr. Newcomb’s own experience, it also provides for internships for high school students and fellowships at NINDS.

Stephen J. Solarz Memorial Fund The Stephen J. Solarz Memorial Fund was established by Nina Solarz in memory of her husband, former Congressman Steve Solarz, to support the research of Dr. David Schrump at the National Cancer Institute. Dr. Schrump’s pioneering research in the field of thoracic oncology led to the treatments that allowed Steve to live years beyond what otherwise would have been possible. Before he died, Nina and her family dedicated themselves to supporting Dr. Schrump’s research so that other patients might benefit from even better treatments.

Foundation for the National Institutes of Health

The Solarz Fund also supported development of another kind of vaccine that can be used to immunize cancer patients if their tumor cells do not grow sufficiently to make a personalized vaccine. Dr. Schrump now plans to enroll participants in the vaccine trial.

Stephen E. Straus Fund Established by Bernard and Barbro Osher in 2006, this fund honors the founding director of the NIH’s National Center of Complementary and Alternative Medicine (NCCAM), the late Dr. Stephen E. Straus. It supports the Stephen E. Straus Distinguished Lecture in the Science of Complementary and Alternative Medicine, an annual lecture that brings leading figures in science and medicine to the NIH to speak about their perspective on the field of complementary and alternative medicine. Open to the public, the lecture is videocast and archived on the NCCAM website.

W W W . F NIH . OR G | 35


and Forward

Endowments Through endowment gifts, donors ensure perpetual

Endowments in support of the Edmond J. Safra Family Lodge

support for a variety of research and educational

Through endowment gifts, donors ensure perpetual

initiatives at the Foundation for the NIH. The annual

support to the Edmond J. Safra Family Lodge for its

investment income generated by an endowment

operations and for the continued comfort of its guests.

fund supports program expenses, while the principal

John I. and Elaine K. Gallin Endowment

remains intact to ensure future funding.

The Gallin Endowment provides amenities for

Sallie Rosen Kaplan Fund for Women Scientists in Cancer Research

family members of patients participating in clinical trials at the NIH.

The Kaplan Fund, established in 2000, provides support for the Sallie Rosen Kaplan Fellowships for Women

GlaxoSmithKline Endowment

Scientists in Cancer Research. These post-doctoral

The GlaxoSmithKline Endowment supports

fellowships are awarded to one or more outstanding

programs and activities for families of patients,

female scientists at the National Cancer Institute.

including services that help residents stay in touch with employers and loved ones.

Norman P. Salzman Memorial Fund Dr. Norman P. Salzman’s family, colleagues and

Harry and Jeanette Weinberg Endowment

friends remember the legacy of this noted pioneer

The Weinberg Endowment supports Edmond J.

in molecular biology through contributions to the

Safra Family Lodge operations and maintenance—

Salzman Memorial Fund, which supports the annual

ensuring that guests are provided a comfortable

Norman P. Salzman Memorial Award and Symposium

home away from home for years to come.

in Virology. The half-day symposium addresses key topics in virology and immunology and presents an award to a young researcher, in recognition of Dr.

2010

Salzman’s mentorship of so many younger scientists.

The FNIH joins Facebook.

A grateful family anonymously gives back to the NIH Clinical Center— more than 50 years after their young daughter was successfully treated there—making generous gifts through the FNIH in support of lung cancer research.

The Biomarkers Consortium announces the launch of the I-SPY 2 TRIAL, a five-year, $25 million Phase 2 clinical trial that uses biomarkers and adaptive trial design to “personalize” the development of new breast cancer drugs and reduce the time and cost of approving them. This is the first large-scale clinical trial sponsored and managed by the Foundation.

36 | 2 0 1 1 A N N U A L R E P O R T

SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS) launches in partnership with NHLBI and six private-sector partners.

OMOP completes its methods feasibility and methods performance testing and characterization experiments; methods library completed and posted online.

ADNI 2 launches and begins enrollment of participants at an earlier stage of mild cognitive impairment and introduces new imaging techniques to improve understanding of how the brain changes as Alzheimer’s disease progresses.

The FNIH-managed GCGH initiative discovers new approaches in delivering traditional vaccines without the need for injection or refrigeration.


What You Can Do There are many ways to partner with the FNIH and make a meaningful impact on human health. Together, we can continue advancing scientific discovery and medical breakthroughs that will help diagnose and treat the most devastating diseases of our time. • Give Where It’s Needed Most: By making a gift to the FNIH and allowing us to strategically apply it where the need is greatest, you help develop emerging program areas and new partnerships.

• Establish an FNIH Fund or Endowment: Make a meaningful, lasting impact in a specific disease area that is important to you or a loved one by making a significant investment in the FNIH. • Give Through the Workplace: Multiply the impact of your donation through your employer’s Matching Gift Program; or, if you’re a federal employee, make us your charity of choice in the Combined Federal Campaign (CFC#29165).

• Join the Discovery Society: Supporters who give $1,000 or more annually receive special acknowledgement, invitations to exclusive events and programs and other unique benefits (See page 39). • Get your Company Involved: Join the FNIH Corporate Patron Society and become a key partner in advancing human health worldwide. • Honor or Memorialize Someone Special: Pay tribute to your NIH physician, family member or friend on a special occasion; or, ask friends and relatives to make donations in memory of a special person in lieu of flowers.

• Join the Legacy Society: Include the FNIH in your estate plans to ensure that the work that is important to you continues for generations to come. • Stay in Touch: For real-time updates follow us on Facebook at www.facebook.com/FNIHorg, Twitter @FNIH_Org, or our blog at www.fnih.org/press/blogs.

Mail your philanthropic investment using the enclosed response envelope. Or give online at www.fnih.org. To learn more about these opportunities, please contact Caite Gilmore at

The FNIH receives a grant from the Bill & Melinda Gates Foundation for the Identification of High-quality HITS for Tuberculosis project for tuberculosis drug discovery. See page 14.

Popular morning talk show Live! With Regis and Kelly hosts the 2010 High Heel-AThon benefiting the FNIH in support of The Heart Truth®.

2011

301-594-2612 or cgilmore@fnih.org.

The FNIH “tweets” for the first time on Twitter.

For the sixth consecutive year, renowned composer and conductor Marvin Hamlisch performs a holiday concert at the Edmond J. Safra Family Lodge. See page 30.

The FNIH joins the NHLBI to spread The Heart Truth® message through its support of the Red Dress Collection 2011 Fashion Show. See page 28.

The FNIH launches the first U.S.-Russia Scientific Forum Planning Meeting supported by a $1.2 million gift from Eli Lilly and Company. See page 30.

Foundation for the National Institutes of Health

The FNIH launches first e-Newsletter.

The FNIH’s Biomarkers Consortium launches a trial to develop diabetes diagnostic tools.

The FNIH receives grants from the Bill & Melinda Gates Foundation for the renewal of CTC-VIMC and for development of a secondgeneration broadly neutralizing antibody product to prevent HIV-1 infection in humans.

W W W . F NIH . OR G | 37


and Forward

Financial Summary REVENUE AND SUPPORT Contributions Grants

2011 2010 53,307,415

55,096,888

7,184,662

8,028,743

Administrative fee

336,864

300,796

Government appropriations

486,000

500,000

Investment earnings

83,763

173,518

In-kind contributions

2,037,266

1,564,550

Donated services

44,892

Return of contribution

-

TOTAL REVENUE AND SUPPORT

63,480,862

212,949 (954,517) 64,922,927

EXPENSES AND CHANGES IN NET ASSETS PROGRAM SERVICES Fellowships and training programs

1,486,681

1,687,123

Memorials, awards and events

3,712,399

1,644,425

38,516

45,399

Research Partnerships

44,259,013

48,914,764

TOTAL PROGRAM SERVICES

49,496,609

52,291,711

Capital Projects

SUPPORTING SERVICES Management and general Fundraising TOTAL SUPPORTING SERVICES TOTAL EXPENSES

2,944,238

2,943,788

145,190

160,144

3,089,428

3,103,932

52,586,037

55,395,643

CHANGE IN NET ASSETS

10,894,825

9,527,284

NET ASSETS BEGINNING OF YEAR

73,538,119

64,010,835

NET ASSETS AT END OF YEAR

84,432,944

73,538,119

The Foundation’s audited statements are available on request.

2011 REVENUES

2011 EXPENSES Contributions 84%

Grants 11% Other Revenue 5%

38 | 2 0 1 1 A N N U A L R E P O R T

Research Partnerships 84%

Education and Events 10% Management and Fundraising 6%


Giving Societies Discovery Society

Trailblazer ($25,000+)

The Foundation for the National Institutes of Health

All of the above benefits, plus:

offers individuals a powerful way to help advance science, discovery and innovation. Membership in the Discovery Society is one of them. Members of this distinguished group receive special acknowledgement, invitations to exclusive events and programs and other unique benefits.

Explorer ($1,000+) • Tour of the NIH campus and Clinical Center for you and one guest • Invitations to FNIH programs and special events • Subscription to the FNIH’s online newsletter • Recognition of support on the FNIH website and in the Annual Report

Investigator ($5,000+) All of the above benefits, plus: • Special lunch and tour of the NIH campus and Clinical Center for you and three guests • Invitation to annual Holiday Luncheon

Pioneer ($10,000+) All of the above benefits, plus: • Opportunity to name a garden bench at the Edmond J. Safra Family Lodge*

• Opportunity to name a small guest suite or gazebo at the Edmond J. Safra Family Lodge* • Invitation to annual Board of Directors dinner

Visionary ($50,000+) All of the above benefits, plus: • Opportunity to name a large guest suite at the Edmond J. Safra Family Lodge* • Invitation to exclusive roundtable discussions with Board of Directors • Participation in high-level partnership meetings, briefing sessions and conference calls on current FNIH programs

Catalyst ($100,000+) All of the above benefits, plus: • Opportunity to name a lounge or hall at the Edmond J. Safra Family Lodge* • Lunch and behind-the-scenes tour of the campus and Clinical Center with senior leadership • Special invitation to exclusive VIP event * All naming opportunities will extend throughout the duration of the campaign for the Edmond J. Safra Family Lodge.

• Opportunity for your child to participate in Young Scientist Day

A bench at the Edmond J. Safra Family Lodge garden offers people a peaceful place to rejuvenate and can be dedicated to a loved one.

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 39


and Forward

Donors The Foundation for the NIH would like to thank the many corporations, private foundations, associations and individuals who generously provided financial and in-kind support to the Foundation and its programs during 2011. Restricted gifts support many varied initiatives, including complex biomedical research programs; educational efforts such as fellowships, lectures and symposia that train scientists and help them build their careers; and specific laboratories or areas of scientific research at the NIH. Unrestricted gifts support core operations and enable the Foundation to develop emerging program areas and new partnerships.

The Foundation is very efficient in managing the private sector’s investment. Of every dollar spent by the Foundation, 94 cents are used to support programs and just six cents for administration and fundraising. In testament to the FNIH’s efficient management of your investment, we have been awarded—or five consecutive years—four stars by Charity Navigator. This top ranking recognizes that we execute our mission in a “fiscally responsible way, and outperform most other charities.” The Foundation gratefully acknowledges the following donors and partners who made gifts or pledges of $250 or more during 2011. The Foundation for the NIH makes every attempt to list donors according to their wishes. Please call 301-402-5311 if you have any questions.

$5,000,000+ Bill & Melinda Gates Foundation 10 Merck Sharp & Dohme Corp. 14 $2,500,000 – $4,999,999 Johnson & Johnson 11 Novartis Pharmaceuticals Corporation12 Pfizer Inc. 14 Sanofi * 10 Takeda Pharmaceuticals North America, Inc. 3 $1,000,000 – 2,499,999 Abbott Laboratories 4 Alzheimer’s Association 7 AstraZeneca LP 10 The Coca-Cola Company 4 Fondation d’entreprise La Mondiale GlaxoSmithKline 13 Eli Lilly and Company 12 The McKnight Brain Research Foundation 6 Pharmaceutical Research and Manufacturers of America (PhRMA) 7 $500,000 – $999,999 Arthritis Foundation 2 Bausch & Lomb Bayer HealthCare Pharmaceuticals, Inc. 4 Biogen Idec Inc. Boehringer Ingelheim Pharmaceuticals, Inc. 3 Critical Path Institute Foundation for Burkitt Lymhoma Research 2 In memory of Xavier Martin National Institutes of Health 16 Bob and Sally Newcomb Novo Nordisk Pharmaceuticals, Inc. Roche 5 $250,000 – $499,999 Amgen, Inc. 9 Belk, Inc.

40 | 2 0 1 1 A N N U A L R E P O R T

Bioiberica Bristol-Myers Squibb Company 12 Eisai Inc. 5 GE Healthcare 3 The Bernard Osher Foundation 3 Quantum Leap Healthcare 2 Swarovski North America, Ltd. 2 $100,000 – $249,999 Alexandria Real Estate Equities, Inc. Amylin Pharmaceuticals, Inc. 2 Avon Foundation for Women Centocor, Inc. Daiichi Sankyo, Inc. 2 Dairy Research Institute The Dannon Company, Inc. 2 Gerber Foundation IBEX Pharmaceuticals, Inc. Institut De Recherches Internationales Servier 2 Johnson & Johnson * 11 Robert Wood Johnson Foundation 8 Meso Scale Diagnostics, LLC 3 NYCOMED GmbH 2 Safeway Foundation Side-Out Foundation SoBran, Inc. Verizon 2 $50,000 – $99,999 Alzheimer’s Drug Discovery Foundation Ambassador and Mrs. Hushang Ansary In memory of Stephen J. Solarz Biotechnology Industry Organization 4 Burroughs Wellcome Fund 7 Capital Technology Information Services, Inc. 2 Cerexa, Inc. Cubist Pharmaceuticals, Inc. DePuy Mitek, Inc. Duke University School of Medicine Forest Laboratories, Inc. Estate of Charles Harris Innate Pharma

Institute for the Study of Aging 2 Intel Corporation 2 McKesson Corporation 2 Nabriva Therapeutics Philips PhRMA Foundation 4 The Rockefeller Foundation Mrs. Lily Safra 10 Trius Therapeutics United Nations Foundation 2 The Walt Disney Company $25,000 – $49,999 Actelion, Ltd. Amway AOL, Inc. AT&T Inc. 2 Beckman Research Institute of the City of Hope BioClinica, Inc. 2 BioVendor Laboratorni medicina a.s.* Buffy and William Cafritz 8 Doris Duke Charitable Foundation 9 Hogan Lovells 2 Incyte Corporation Juvenile Diabetes Research Foundation International 2 Estée Lauder Companies Inc. Medpace, Inc. 3 Dr. and Mrs. Paul M. Montrone 14 National Initiative for Children’s Healthcare Quality (NICHQ) The Procter & Gamble Company 2 Qualcomm, Inc. 3 RottaPharm-Madaus Synarc, Inc. 4 UnitedHealthcare Services, Inc. Vodafone mHealth Solutions $10,000 – $24,999 Bernard W. Abrams Family Foundation, Inc. 3 In memory of Bernard W. Abrams American Orthopaedic Society for Sports Medicine (AOSSM)

AMS Foundation for the Arts, Sciences and Humanities 7 The Association for Frontotemporal Degeneration Basilea Pharmaceutica International Ltd. William C. and Paula L. Bradley 4 Buffy and William Cafritz Family Foundation 3 Celgene Corporation 2 Cempra Pharmaceuticals Chiesi Farmaceutici S.p.A. 2 Commerce One BPO, LLC Continua Health Alliance 2 Friends of Cancer Research 2 General Mills, Inc. 2 Genome British Columbia 2 Genzyme Corporation Jack Gramlich Foundation Hempling Foundation For Homocystinuria Research Huntington’s Disease Society of America Illumina, Inc. International Biomedical Research Alliance Howard H. and Jacqueline K. Levine In memory of Stephen J. Solarz Freda C. Lewis-Hall, M.D., FAPA Metanomics Health GmbH Myriad RBM 2 Parkinson’s Disease Foundation Steven and Jann Paul The Pew Charitable Trusts 3 Professional Landscape Management Services * Profilo Holding In memory of Stephen J. Solarz Jillian Sackler, D.B.E. 9 Dr. and Mrs. Charles A. Sanders 15 Jane M. Sayer, Ph.D. 10 Mr. Gerald R. and Dr. Ellen V. Sigal 9 Simon Property Group 2 Nina Solarz 2 In memory of Stephen J. Solarz Vertex Pharmaceuticals, Inc.


$5,000 – $9,999 Anonymous Alliance Health Networks, Inc. American Academy of Dermatology American Academy of Physical Medicine and Rehabilitation American College of Rheumatology, Inc. American Diabetes Association 2 American Occupational Therapy Association American Physical Therapy Association American Psychological Association American Society for Bone and Mineral Research Association of Academic Physiatrists Bach Pharma, Inc. Battelle Ronald and Barbara Berke 2 In memory of Jenny Berke BGI - Shenzhen Luther W. Brady, M.D. 5 In honor of Charles A. Sanders Brent Foundation 2 Frank C. and Marcia M. Carlucci In memory of Stephen J. Solarz Dr. and Mrs. James H. Cavanaugh 4 Center For Women’s Health Research 2 Clothes Off Our Back, Inc. 3 The Columbus Foundation Consumer Electronics Association Dionex Corporation 2 Anthony S. Fauci, M.D. and Christine Grady, Ph.D. Food and Drug Aministration Alumni Association Inc. Genome Canada Miles Gilburne and Nina Zolt 2 GlaxoSmithKline * 13 Global HIV Vaccine Enterprise William T. Grant Foundation Margaret Grieve In memory of Stephen J. Solarz Kay A. Hart In memory of Stephen J. Solarz Fred and Noreen Hassan 2 Hereditary Disease Foundation Jean Linton 9 Lupus Foundation of America March of Dimes Birth Defects Foundation Stephen M. McLean MO BIO Laboratories, Inc. 2 Drs. Martin J. and Ann Murphy 6 In honor of Charles A. Sanders Muscular Dystrophy Association National Osteoporosis Foundation National Pharmaceutical Council New England Biolabs 3 Donna Nichols 2 In memory of Jay Nichols OpGen, Inc.

Orthopaedic Research and Education Foundation Osteoarthritis Research Society International, Inc. 2 Ron and Joy S. Paul 2 In honor of Fred and Nancy Sommer PepsiCo, Inc. Victor Pinchuk Foundation In memory of Stephen J. Solarz Promega Corporation Proof Centre of Excellence 2 Quintiles Transnational Corporation 2 Radiological Society of North America 3 Real Time Genomics, Inc. 2 Robert E. Roberts, Ph.D. 3 Rodale, Inc. 2 Second Genome Solomon H. and Elaine B. Snyder 11 Society of Investigative Dermatology SunTrust Banks, Inc. Ullmann Family Foundation 3 United States Pharmacopeial Convention University of British Columbia Steve and Chris Wilsey 4 $1,000 – $2,499 Anonymous ABC Alnor Oil Company American Academy of Orthotists & Prosthetists American Orthotic Prosthetic Association John Bennett Alice S. Cho and James J. Bergera James J. and Janet Blanchard In memory of Stephen J. Solarz Mr. Zachary T. and Dr. Kathy Bloomgarden 3 Board of Certification/Accreditation, International Booz Allen Hamilton Inc. 4 Samuel and Gail Broder 11 Karen Brooks In memory of Stephen J. Solarz Susan Buchanan Scott E. Campbell, Ph.D. 2 Mr. Charles Cerf and Dr. Cynthia E. Dunbar Ross T. Chambers The Coca Cola Foundation Ms. Laura Curtin 3 In memory of Richard Curtin Stewart Daniels 3 Sanford M. Dawsey In memory of Dr. Arthur Schatzkin Downey McGarth Group, Inc. In memory of Stephen J. Solarz The Essence of Red Committee Ronald G. Evens, M.D. 5 In honor of John I. Gallin

Foundation for the National Institutes of Health

Joseph M. Feczko, M.D. and Leighton K. Gleicher 4 James M. Felser, M.D. 2 Thomas L. and Ann B. Friedman In memory of Stephen J. Solarz Randy K. Glantz and Binaife A. Davar In memory of Stephen J. Solarz Gary Grossman In memory of Stephen J. Solarz Thomas H. and Rita R. Hassall 3 Harley Anderson Haynes, M.D. 2 Steve and Sally Herman In memory of Dr. Arthur Schatzkin Roderick M. and Carla A. Hills In memory of Stephen J. Solarz Eric Hirschhorn In memory of Stephen J. Solarz E.A. Holtzman Foundation In memory of Stephen J. Solarz Joshua J. Howard In memory of Stephen J. Solarz IQ Solutions 2 Mahnaz Ispahani In memory of Stephen Solarz Alan G. Johnson In memory of Annetta Johnson Linda H. Kamm In memory of Stephen J. Solarz Nancy Kaplan 2 Bernard H. and Georgina E. Kaufman 2 Jules and Lynn Kroll Gail Leese 2 Franz Leichter In memory of Stephen J. Solarz Jonathan D. Levine In memory of Stephen J. Solarz Stephen K. and Suzanne Levine In memory of Stephen J. Solarz James and Marie Malaro In memory of Lucille M. Decker Robert and Margaret McNamara Foundation 2 National Association for the Advancement of Orthotics & Prosthetics Stephen A. Novick In memory of Stephen J. Solarz Matthew W. O’Neill 5 In memory of Dean O’Neill Izamar Ontiveros Mattison C. and Robyn Painter In memory of Jay Nichols The Pannonia Foundation In memory of Stephen J. Solarz Amy and John Porter 12 Rivermap DNA Laboratory Robert E. Roberts, Ph.D. * 3 Stanley O. Roth In memory of Stephen J. Solarz Lenore R. Salzman 14 In memory of Norman P. Salzman Estate of Frances H. Saupe 4

Dr. and Mrs. Howard K. Schachman 7 Scleroderma Research Foundation Joel P. and Marcia Selden In memory of Stephen J. Solarz Sigma-Aldrich Corporation 3 William S. Singer 2 In memory of Stephen J. Solarz Albert H. and Lillian Small 3 The Eddie and Jo Allison Smith Family Foundation In honor of Lanier Swann Fred S. and Nancy T. Sommer In honor of Howard Fine Dr. and Mrs. Stephen P. Spielberg 9 Mark A. Spiteri 5 Dr. and Mrs. David J. Steinberg In memory of Stephen J. Solarz Thermo Fisher Scientific Inc. Samuel O. Thier, M.D. and Paula Thier 6 United States Bone and Joint Decade George F. Vande Woude, Ph.D. Tracy and Richard Waggoner In memory of Jay Nichols Mai Wang Howard M. and Nancye C. Weisberg 3 Lisa N. Whitten 2 In memory of Jay Nichols E. Bell Young In memory of Thomas E. Malone Drs. Elias A. and Nadia Zerhouni 3 $500 – $999 Anonymous James Bayless In memory of Stephen J. Solarz The Honorable and Mrs. William McCormick Blair, Jr. 13 Boehringer Ingelheim Pharmaceuticals, Inc.* 3 Stuart Bondurant and Susan Ehringhaus 4 Tino and Dawn Calabia In memory of Stephen J. Solarz Rina Caniza In memory of Stephen J. Solarz Janet Carlson and Daniel Balliet 3 Conservation International In memory of Stephen J. Solarz Lisa Crafford In memory of Stan Nebinski Janet S. DeGilio 2 Eugene and Mary Dionne In memory of Stephen J. Solarz Nicholas M. and Jacqueline E. Ferriter 2 James and Karen Gavic 2 Stanley and Eve Geller 6 In memory of Norman Salzman Ken and Yvette Guidry 5

W W W . F NIH . OR G | 41


and Forward

Mary Frances Cotch and B. Fenton Hall 7 Robert Harris In memory of Dr. Arthur Schatzkin Amy W. Hawthorne 2 In memory of Stephen J. Solarz Eva C. Holtz 2 Laurel Jacobson 2 In memory of Stephen W. Jacobson Richard Jonas and Katherine Vernot-Jonas 4 Julep Nail Parlor Mark Kaufman and Judith L. Harris In memory of Dr. Arthur Schatzkin Ron Kopicki and Ann Ashby The Honorable and Ms. G. Oliver Koppell In memory of Stephen J. Solarz Sam Lippman 2 Mattlin Foundation 3 National Marfan Foundation Nature Publishing Group Ruth Nolte Dr. Gilbert S. Omenn and Mrs. Martha Darling 4 Mara Polan In honor of Fred and Nancy Sommer Charles Radcliffe and Herve Verhoosel In memory of Stephen J. Solarz James and Lora Rodenberg 2 Armand Rodriguez Gregory Roper Robert and Marjorie Rosenberg Douglas E. Schoen 2 In memory of Stephen J. Solarz David G. and Carole L. Schultz Stephen C. Syne Diane M. Szolyga Anne Thiebaut In memory of Dr. Arthur Schatzkin The Drs. Termoulet 3 Jon and Kristin Vaver 4 Michael and Marianne Walter Mrs. Henry P. Wheeler 11 Fred C. Williamson 2 Matthew Zimmerman 2 In memory of Brent K. Herrold $250 – $499 Anonymous Dr. and Mrs. N. Kirby Alton, The Alton Foundation 2 Paul Bach In memory of Stephen J. Solarz Jill H. Barr 3 In memory of John L. Barr

42 | 2 0 1 1 A N N U A L R E P O R T

William G. Barsan, M.D. 2 Ann Beck 4 Joan Beck Edward Brannan Dr. and Mrs. Jacob A. Brody 3 Cambridge Isotope Laboratories, Inc. 2 Raymond W. Clement 3 Michael Conforti In memory of Stephen J. Solarz Craig Corbitt and Nancy Stoltz 2 Susan G. Davis 3 Josephine F. de Give In memory of David de Give Nancy Dougherty In memory of John N. Miller III Carol and John Eddy 4 Scott Edgerton Brenda K. Edwards In memory of Dr. Arthur Schatzkin Dawn Fidaleo 2 Seth P. Forster 5 Peggy J. Gerlacher14 In memory of John D. Gerlacher Aaron Gibson 2 Drs. David Golan and Laura Green Erica L. Goldberg 2 In memory of Jeffrey Kauffman Jonathan Greenblatt and Linda A. Adams 2 In memory of Stephen J. Solarz Michael C. and Patricia M. Greer Sigurd Hermansen In memory of Dr. Arthur Schatzkin Jonathan Hiatt In memory of Dr. Arthur Schatzkin Rachel and Jamie Hirsch Stephanie L. James, Ph.D. Pamela Jeffcoat 3 Michelle Jezycki Lisa Johnson Harry and Marilyn Karasov 2 Angelos Kleanthous Dr. and Mrs. Ronald W. Lamont-Havers 2 The Lannum Family In honor of Michael Assenza The Paul Laxalt Group In memory of Stephen J. Solarz Paul and Carole Laxalt In memory of Stephen J. Solarz Michael Lenardo, M.D. Chris Lenker Robert and Bonnie Livingston In memory of Stephen J. Solarz Louis Vuitton North America Roger A. and Barbara Michaels 2

Lilly Minkove 2 W. Tyler and Christy R. Mistr In honor of Chris Battle Reverend and Mrs. Robert H. Naylor 2 Rosie Nebenhaus Ross In memory of Stephen J. Solarz Anne Newman, M.D. In memory of Dr. Arthur Schatzkin No Tears Learning Judith A. Nowak, M.D. Yikyung Park In memory of Dr. Arthur Schatzkin Mitchell Pines 5 Lisa Prickett In memory of Stephen J. Solarz Ramerica International, Inc. 2 In memory of Stephen J. Solarz David C. and Marilyn Reed Charles and Lynda J. Robb In memory of Stephen J. Solarz Fu-Meei Y. Robbins Gary M. Roggin, M.D. Walter G. Rostykus and Catherine Elliott-Rostykus 3 Marvin Schmeiser 2 Michelle Schumaker Marilyn M. Seastrom 2 Eugene Sofer and Judith Bartnoff 2 In memory of Stephen J. Solarz Alan Solomon, M.D. 2 Rainer F. Storb, M.D. Donald Thompson William Tolentino and Andre Bailey 3 James Tucker 4 Vehbi Koc Vakfi In memory of Stephen J. Solarz Julie Wagshal Robert C. Watson, Jr. Thomas E. Wellems, M.D., Ph.D. 3 John H. Wilson 3 Howard and Julie Wolf-Rodda 5 Justin Wyman In memory of Vicki Triantos Shrum Joyce A. Yarington 8 In memory of Edward Riley Joel Yesley 4 Charles W. Zimmerman 4 * indicates Gifts in Kind [superscript] recognizes donors who have given consecutively for the stated number of years


HONORARIUM GIFTS

MEMORIAL GIFTS

You can honor a friend or family member for an important occasion with a gift to the Foundation for the NIH. It is a wonderful way to send good wishes for a birthday or anniversary, thanks to a friend or doctor, or congratulations for retirement, a job well done or graduation. Please include the name and address of the individual being honored so that acknowledgement of your kind donation can be sent. In 2011, the Foundation received gifts in honor of the following individuals.

Contributions are given to the Foundation for the NIH at the request of family members in memory of loved ones. These generous contributions enhance our ability to support the NIH in its mission to improve health, by forming and facilitating publicprivate partnerships for biomedical research, education and training. We extend our sympathies to the family and friends of those memorialized below.

Annette B. Abrams Michael Assenza Chris Battle Connie Becker Howard A. Fine Betty J. Gaffney John I. Gallin Kurt Gerstmann Fred A. Gill Carter Mae Hayes Dianne Hepke Stephen I. Katz Rajeev Malik Matt Maples

Tom May Read Mecleary Turner Pierce Alan Rosenberg Alison B. Rubenstein Charles A. Sanders Alfred Sommer Fred S. Sommer Nancy T. Sommer Lanier Swann Kristen R. Thompson Camilo Toro Thomas Tuten

LEGACY SOCIETY The Legacy Society recognizes individuals who have informed us that they have named the Foundation for the NIH as a beneficiary in their will or estate plan. These legacy gifts can support a specific NIH program, area of research or other identified need, or they may provide unrestricted support to the Foundation. We thank the following individuals who have named the Foundation as a beneficiary. Anonymous Judy Belous The Honorable and Mrs. William McCormick Blair, Jr. Paula L. Bradley Patricia S. Kohlen Drs. Zell and Emily Kravinsky Patricia Nowosacki Robert E. Roberts, Ph.D. Jane M. Sayer, Ph.D. Dr. and Mrs. Robert F. Wagner Susan M. Wall, M.D.

Bernard W. Abrams Arlene Alexander Jack Arnesen John L. Barr Jenny Berke Igor Birman Doris Blume Kris Blume James S. Brockman Denis J. Buksa Robert Burns Bennett Camhi Marcella Cheslow Holzman John Cookendorfer Brian Crehan Richard Curtin Annie L. Davis David de Give John L. Decker Lucille M. Decker David Derse Sylvia Diamond Sherita Durbin John D. Fout Paul A. Gattini John D. Gerlacher Brent K. Herrold Nicholas P. Humy Stephen W. Jacobson Annetta Johnson Mark A. Kapouralos Jeffrey E. Kauffman

Marilyn Kotwal Panagiota Koutroubinis Michael Kuchinsky Erin M. Kurtz Catherine Malavendra Thomas E. Malone Michael C. Marr Xavier Martin Eyal Michelson Michael T. Middleton Carlton Miller John N. Miller Stan C. Nebinski Arthur Nepiarsky Jay Nichols Dean R. O’Neill Melissa Palmer Richard C. Potts Jennifer R. Price Lindsey Rensch Edward Riley Morton Rolnick Myrna L. Rubenstein Norman P. Salzman Arthur G. Schatzkin Abe Schwartz Amy Siegel Stephen J. Solarz Vicki Triantos Shrum Theresa Valenti Francis E. Weber Robert A. Welch

fundraising |

Money raised for every dollar of government appropriation received

$21

$27

$29

$125

$158

$164

$177

$148

$135

$134

$1 $1

$1

$1

$1

2002

2003

2004

2005

2006

Foundation for the National Institutes of Health

$1

$1

2007

2008

2009

2010

2011

W W W . F NIH . OR G | 43


and Forward

2011 Board of Directors Officers

Chairman

Vice Chairman

Treasurer

Secretary

Charles A. Sanders, M.D.

The Honorable John Edward Porter

Paul M. Montrone, Ph.D.

Mrs. William McCormick Blair, Jr.

Retired Chairman and CEO Glaxo, Inc.

Hogan Lovells

Chairman, Perspecta Trust Executive Chairman & Founding Partner, Liberty Lane Partners

Director Emeritus Albert and Mary Lasker Foundation

Kathy Bloomgarden, Ph.D. Chief Executive Officer, Ruder Finn Inc.

Ellen V. Sigal, Ph.D. Chairperson, Friends of Cancer Research

Mrs. William (Buffy) N. Cafritz Trustee, The John F. Kennedy Center for the Performing Arts

Solomon H. Snyder, M.D. Director, Department of Neuroscience Johns Hopkins University School of Medicine

Joseph M. Feczko, M.D. Retired Senior Vice President and Chief Medical Officer, Pfizer Inc

Freda C. Lewis-Hall, M.D., FAPA Chief Medical Officer, Senior Vice President, Pfizer Inc

Stephen P. Spielberg, M.D., Ph.D. Marion Merrell Dow Endowed Chair in Pediatric Pharmacogenomics Director, Center for Personalized Medicine and Therapeutic Innovation Professor of Pediatrics and Pharmacology Children’s Mercy Hospital and Clinics, Kansas City

Caroline Kovac, Ph.D. Retired General Manager, IBM Healthcare and Life Sciences

Samuel O. Thier, M.D. Professor of Medicine and Health Care Policy, Emeritis Harvard Medical School, Massachusetts General Hospital

Sherry Lansing Founder and Chair, The Sherry Lansing Foundation

Anne Wojcicki Co-Founder, 23andMe

Miles Gilburne Managing Member, ZG Ventures, LLC

Ann Lurie President, Lurie Investments, Inc. President and Treasurer, Ann and Robert H. Lurie Foundation President, Africa Infectious Disease Village Clinics, Inc. Martin J. Murphy Jr., Ph.D. Founding Chairman and Chief Executive Officer, AlphaMed Consulting, Inc. Steven M. Paul, M.D. Assistant Professor of Neuroscience, Weill Cornell Medical College Philip A. Pizzo, M.D. Dean, Stanford University School of Medicine Jillian Sackler, D.B.E. President and CEO, AMS Foundation for the Arts, Sciences & Humanities Mrs. Lily Safra Chairman, The Edmond J. Safra Philanthropic Foundation Kurt L. Schmoke Dean, Howard University School of Law

44 | 2 0 1 1 A N N U A L R E P O R T

Director Emeritus

Paul Berg, Ph.D. Cahill Professor in Biochemistry (Emeritus), Stanford University School of Medicine Honorary Directors

Luther W. Brady, M.D. Hylda Cohn/American Cancer Society, Professor of Clinical Oncology and Professor, Department of Radiation Oncology Drexel University College of Medicine Patrick C. Walsh, M.D. University Distinguished Service Professor, James Buchanan Brady Urological Institute Johns Hopkins Medical Institutions Ex Officio Non-Voting Directors

Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Margaret Hamburg, M.D. Commissioner, Food and Drug Administration


2011 Foundation for the NIH Staff Executive Director’s Office

Development

Scott E. Campbell, Ph.D. Executive Director and CEO

Julie Wolf-Rodda, M.A. Director, Partnership Development

Ann Ashby, M.B.A. Deputy Executive Director

Andrea Baruchin, Ph.D. Director, NIH Relations

Jenna Mills Palfrey Communications Manager

Erika Tarver NIH Projects Officer

Tara L. Jacob Operations Administrator and Senior Executive Assistant

Alison Drone, M.A. Partnership Development Officer

Joshua A. Walker Senior Executive Assistant Elizabeth S. Johns Operations Assistant Kai Yee Web Administrator Michelle Jezycki, MAOM Director, Human Relations Finance

Julie Tune, CPA, CFE Chief Financial Officer Eva Coyne, CPA Accounting Manager Noemi B. Rodriguez Staff Accountant Peggy J. Gerlacher Operations Associate Michelle McGill Staff Accountant Marketing And Strategic Alliances

Richard M. Scarfo Director Peggy M. Diab Manager, Events and Marketing

DESIGN: Don Schaaf & Friends, Inc. | www.dsfriends.com

Bonnie Knight Manager, Corporate Relations and Sponsorships Chianti C. Seitz Events Coordinator

Donna Batcho, M.P.A. Partnership Development Officer, Individual and Planned Giving Caitlin Gilmore Partnership Development Officer, Major Gifts

Jan Fowler Executive Assistant Observational Medical Outcomes Partnership (OMOP)

Tom Scarnecchia, M.S. Executive Director Emily Welebob, R.N., M.S. Senior Program Manager, Research Christian Reich, M.D., Ph.D. Senior Program Manager, IT Biomarkers Consortium

David Wholley, M.A. Director David Lee, M.P.A. Deputy Director

Paris L. A. Moore Partnership Development Officer, Biomarkers Consortium

Maria Vassileva, Ph.D. Scientific Program Manager, Metabolic Disorders

William Tolentino Development Systems Administrator

Sonia Pearson-White, Ph.D. Scientific Program Manager, Cancer

Kathy Guire Executive Assistant Science Administration

Stephanie James, Ph.D. Director of Science and Director, Grand Challenges in Global Health Michael Gottlieb, Ph.D. Deputy Director of Science Dennis Lang, Ph.D. Senior Program Coordinator, MAL-ED Rebecca Blank, Ph.D. Scientific Program Manager, MAL-ED

Judy Siuciak, Ph.D. Scientific Program Manager, Neuroscience Karen H. Tountas, Ph.D. Scientific Program Manager, Inflammation & Immunity Jessica Ratay, M.S., CGC Clinical Project Manager Cheryl Melencio Executive Assistant

Susan Powell, M.T.S. Grants Manager Magda Galindo Assistant Grants Manager Susan Wiener, M.A. Project Manager, Grand Challenges in Global Health

Laura Harwood Events Coordinator

Gail Levine, M.A., CRCC Scientific Program Manager, CTC-VIMC

Michael Waterman Executive Assistant

Anna Sambor, M.S. Project Manager, CTC-VIMC

Foundation for the National Institutes of Health

W W W . F NIH . OR G | 45


Partners for Innovation, Discovery, Health 9650 Rockville Pike Bethesda, MD 20814-3999 USA 301-402-5311 www.fnih.org

All rights reserved. This material may be quoted or reproduced without charge for noncommercial purposes only; however, please acknowledge the source. The full text of this report is also available online at www.fnih.org


2011 FNIH Annual Report  

In 2012, the Foundation for the National Institutes of Health (FNIH) celebrates its 15th year in operation. The record of the past 15 years...

Advertisement
Read more
Read more
Similar to
Popular now
Just for you